Published in final edited form as:

Int Rev Cell Mol Biol. 2019 ; 342: 27–71. doi:10.1016/bs.ircmb.2018.07.004.

T Cells and Regulated Cell Death: Kill or Be Killed

Johan Spetz, Ph.D.^{1,2}, Adam Presser, B.S.^{1,2}, Kristopher A. Sarosiek, Ph.D.^{1,2}

¹John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA

²Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Department of Systems Biology, Harvard Medical School, Boston, MA

Abstract

Cell death plays two major complementary roles in T cell biology: mediating the removal of cells that are targeted by T cells and the removal of T cells themselves. T cells serve as major actors in the adaptive immune response, and function by selectively killing cells which are infected or dysfunctional. The selectivity in the T cell recognition and elimination is a highly regulated feature, which in itself involves the death of both autoreactive T cells and T cells which are unable to recognise threats. Moreover, detection of potential threats will result in the activation and expansion of T cells, which upon resolution of the immune response will need to be eliminated. The culling of these T cells can be executed via a multitude of cell death pathways which are used in context-specific manners. Failure of these processes may result in an accumulation of misdirected or dysfunctional T cells, leading to complications such as autoimmunity or cancer. This review will focus on the role of cell death regulation in the maintenance of T-cell homeostasis as well as T cell-mediated elimination of infected or dysfunctional cells, and will summarize and discuss the current knowledge of the cellular mechanisms which are implicated in these processes.

Introduction

Cell death was long considered a passive, uncontrolled process leading to the demise of damaged cells. However, research performed during the last decades has revealed a plethora of cell death modes, both passive as well as active, which are tightly regulated to maintain organismal health (Galluzzi et al., 2018). Importantly, these processes of regulated cell death are crucial for proper development and homeostasis, and are also implicated in the development, progression, and treatment of many different diseases, including those related to the immune system (Anaya et al., 2013; Ardoin and Pisetsky, 2008; Fuchs and Steller, 2011). The broad array of cell death modes has evolved out of a necessity to precisely control cell number and homeostasis with a variety of mechanisms that can achieve certain results while preventing others. For example, pyroptosis is primarily utilized for cell execution when activation of an immune response is needed while apoptosis is largely immunogenically silent (Galluzzi et al., 2017; Martin et al., 2012).

T cells are an integral part of the adaptive immune system, and constitute the largest proportion (45 - 70%) of the peripheral blood mononuclear cells (PBMCs) (Verhoeckx et al., 2015). They have a central role in cell-mediated immunity and the cytotoxic capacity of T cells is instrumental in eliminating pathogens. However, for T cell-mediated immunity to function properly, it needs to be controlled by complex and highly precise mechanisms, both positively and negatively (Janeway et al., 2001). In order for humans to mount an immune response, it is necessary to maintain a large circulating population of T cells that are able to properly recognize and rapidly respond to threats (Bluestone et al., 2010). These threats can be exogenous pathogens such as viruses and bacteria or endogenous threats such as cancerous cells (Janeway et al., 2001). However, if autoreactive T cells are not properly culled, autoimmune disorders can develop, in which T cells attack self-tissues (Grossman and Paul, 2015). This balance is achieved by elimination of autoreactive T cells, mainly in the thymus, although a small population of autoreactive T cells may circulate in the periphery (Arakaki et al., 2014; Green et al., 2003; Hogquist et al., 2005).

On the other hand, upon detection of foreign antigen, expansion of oligoclonal antigen-specific T cells is crucial for the establishment of adaptive immune responses against pathogenic challenges (Grossman and Paul, 2015; Wange and Samelson, 1996). However, following resolution of the immune response and elimination of the response-driving antigen, the expanded T cells are no longer needed. Most of these cells are eliminated via apoptosis, while a small number is conserved to become memory T cells (Li et al., 2017b). This culling of the expanded T cell population serves to prevent unnecessary energy expenditure but also further helps balance self-reactivity and autoimmunity (Kurtulus et al., 2010).

This review aims to summarize the present state of knowledge concerning both of these aspects of cell death regulation in the context of T cells. Namely, 1; which mechanisms of regulated cell death are implicated in the death of unwanted or faulty T cells to maintain homeostasis, and 2; by what means do cytotoxic T cells kill other cells such as viruses, bacteria, or cancerous cells.

Cell death pathways in T cells

The removal of undesired or faulty cells by regulated cell death is a fundamental physiological process which is vital for development, immunity and tissue homeostasis. Furthermore, disruption of the programmed cell death pathways can lead to abnormally high or low rates of cell death, and is associated with many of the diseases that constitute the top causes of death worldwide, including cardiovascular, neurodegenerative, pulmonary, renal and hepatic diseases, as well as cancer (Goilav, 2011; Johnstone et al., 2002; Lozano et al., 2012; Lu et al., 2014; Okouchi et al., 2007; Spetz et al., 2018; Su et al., 1997; Wang, 2014; Whelan et al., 2010). Several different modes of programmed cell death have been described in the literature in numerous biological contexts, and the study of these pathways has been instrumental in explaining the diverse biological processes involved in cell loss (Galluzzi et al., 2018). This section describes the pathways of regulated cell death which have been shown to play a role in the death of autoreactive T cells as well as elimination of activated T cells after resolution of an immune response.

Apoptosis

Apoptosis is the most studied programmed cell death mechanism, and also the primary method of cell death involved in development and homeostasis (Fuchs and Steller, 2011; Galluzzi et al., 2018). Most of the culling of T cells, both concerning auto-reactive T-cells and activated T cells which have played out their role, is performed via apoptotic cell death (Clayton et al., 1997; Murphy et al., 1990; Strasser et al., 1991). Apoptosis is tightly involved in the development and selection (both positive and negative) of T cells in the thymus (Figure 1), as well as in the periphery. Defects in apoptotic regulation in T cells are known to either lead to or play a major role in diseases such as lymphoma (Johnstone et al., 2002; Straus et al., 2001) and autoimmune diseases such as systemic lupus erythematosus (Mak and Kow, 2014; Prokunina et al., 2002), rheumatoid arthritis (Hashiramoto et al., 2018; Salmon et al., 1997), and Crohn's disease (Yamazaki et al., 2005). The apoptotic process is mediated via two distinct pathways: the intrinsic (mitochondria-mediated) pathway, and the extrinsic (death receptor-mediated) pathway, both of which are discussed in detail below. These can function independently, but there are also several molecules involved in both pathways through which crosstalk can occur. A common characteristic for both pathways, however, is that they eventually result in activation of cysteine-aspartic proteases (caspases) which initiate and execute degradation of cellular components, in order to induce the morphological changes for apoptosis and prepare the cell for clearance with minimal stress to surrounding tissues (Los et al., 1995; Miura et al., 1993; Ramage et al., 1995; Sabbatini et al., 1997).

The intrinsic apoptotic pathway—The intrinsic apoptotic pathway is regulated by the BCL-2 family of proteins, which contains both pro- and anti-apoptotic members that share conserved sequences called BCL-2 homology (BH) domains and maintain the balance between cell survival and death (Danial and Korsmeyer, 2004). The discovery of BCL-2 and its function in B cell lymphoma led to the identification of a wide range of proteins within the same family, which can be classified as pro-survival, pro-apoptotic activator BH3-only, or pro-apoptotic effector proteins (Tsujimoto et al., 1985; Vaux et al., 1988). These proteins form an intricate signalling network of functional interactions, regulating the integrity of the mitochondrial outer membrane and its potential. Apoptosis is triggered when a pro-apoptotic effector protein (BAX or BAK) is activated by an activator BH3-only protein (Tait and Green, 2013). Intrinsic apoptotic pathway can be triggered by a diverse array of stimuli, such as upstream stress signals (from e.g. chemotherapy, radiotherapy or environmental stressors), growth factor or nutrient deprivation, or developmental cues, to initiate apoptosis and conserve homeostasis or remove damaged cells. To date, 8 different BH3-only proteins have been discovered in mammals (BIM, BID, BAD, BIK, BMF, HRK, NOXA, and PUMA) of which BIM and BID are most potent (Czabotar et al., 2013; Kim et al., 2006; Leshchiner et al., 2013; Letai et al., 2002; Wei et al., 2000). These 8 proteins are characterised by a single, 9-13 amino acid BH domain called BH3, which is required for binding to anti-apoptotic and/or pro-apoptotic effector proteins (Glab et al., 2017). This binding is highly selective and different BH3-only proteins have different binding affinity for different anti-apoptotic and/or pro-apoptotic effector proteins (Czabotar et al., 2014; Sarosiek et al., 2013). The activation of the pro-apoptotic effector proteins BAX and/or BAK results in oligomerization, which causes formation of macro-pores in the mitochondrial outer

membrane, leading to release of cytochrome c and SMAC (second mitochondria derived activator of caspases) into the cytosol (Doerflinger et al., 2015; Lakhani et al., 2006). SMAC functions to inhibit XIAP (X-linked inhibitor of apoptosis protein), which is an inhibitor of the effector caspases (caspase 3 and 7) (Liu et al., 2000; Wu et al., 2000). Cytochrome c, together with dATP, binds to APAF1, forming an oligomeric apoptosome which binds and cleaves pro-caspase 9 into its mature form. This activates downstream caspases (e.g. caspase 3 and caspase 7) that dismantle the cell and promote phagocytosis (Galluzzi et al., 2009; Taylor et al., 2008). However, the anti-apoptotic proteins in this family (e.g. BCL-2, BCL-XL, MCL-1), which contain all BH domains (BH1-4), can block apoptosis by binding and sequestering monomeric BAX/BAK or BH3-only proteins (Czabotar et al., 2014). In order for apoptosis to occur, anti-apoptotic proteins within the cell must be overwhelmed and BAX and/or BAK activated.

Proteins of the BCL-2 family are expressed to various different extents in mammals, and also differ in activation state, depending on tissue type, cell lineage, developmental stage and age (Sarosiek et al., 2017; Wong and Puthalakath, 2008). Depending on the basal state of the molecules in the intrinsic apoptotic pathway, a cell can respond differently to exogenous pro-death signals (Sarosiek and Letai, 2016). Recently, a functional assay called BH3 profiling was developed, which measures the apoptotic priming (proximity of cellular mitochondria to the apoptotic threshold) by delivering titrated doses of distinct proapoptotic signals (BH3 peptides) to mitochondria while monitoring mitochondrial outer membrane permeabilization (MOMP) and subsequent cytochrome c release (Ni Chonghaile et al., 2011; Ryan and Letai, 2013). Considering immune cell apoptosis, PBMCs remain primed throughout life, and BIM in particular is a key regulator in T cells in many different subsets and contexts (Bouillet et al., 1999; Enders et al., 2003; Li et al., 2017a; Sarosiek et al., 2017). Studies in *Bim*^{-/-} mice have shown an accumulation of auto-reactive lymphocytes, lack of T cell culling (negative selection) both in the thymus and periphery, and signs of autoimmune disease later in life (Bouillet et al., 2002; Hildeman et al., 2002; Hughes et al., 2006). However, for this autoimmunity to fully manifest, there is evidence to suggest that defects in the extrinsic apoptotic pathway are also necessary (Hughes et al., 2008). Mice deficient in both BIM and PUMA have been shown to spontaneously develop autoimmunity in several different organs and an accumulation of mature, single-positive (CD4⁺ or CD8⁺) T cells, which also suggests defects in thymic T cell culling (Gray et al., 2012). Peripherally, BIM is also involved in controlling the homeostasis of CD4⁺ and CD8⁺ T cells, and is the major mediator of T-cell elimination after the peak of immune responses (Bouillet et al., 2002; Hildeman et al., 2002; Kurtulus et al., 2015, 2011; Pellegrini et al., 2003; Weant et al., 2008; Wojciechowski et al., 2007, 2006). In contrast to CD4⁺ T cells, CD8⁺ T cells have higher rates of apoptosis (Foulds et al., 2002), which may be dependent on the activity of cytochrome c oxidase (COX) and response to reactive oxygen species (ROS) during differentiation and/or activation (Schüll et al., 2015; Tarasenko et al., 2017). Though not as non-redundant as BIM, many of the other BCL-2 family proteins play an important role in T cell development and homeostasis, including BCL-2 in naïve and memory T-cell survival (Nakayama et al., 1993; Veis et al., 1993; Wojciechowski et al., 2007), and in combating BIM to promote CD8⁺ T-cell memory development (Kurtulus et al., 2011); BCL-XL in thymic development (Ma et al., 1995; Zhang and He, 2005), MCL-1 in thymic development

as well as peripheral management of CD4+, CD8+ and regulatory T cells (Dzhagalov et al., 2008; Opferman et al., 2003); and PUMA and NOXA in the control of T-cell expansion and contraction during an immune response (Fischer et al., 2008; Kurtulus et al., 2015; Wensveen et al., 2010). Furthermore, BCL-XL expression has also been shown to be induced by phosphatidylinositol 3-kinase (PI3K) signalling as well as TCR signalling and further enhanced by CD28, 4-1BB, and OX40 costimulation, in an NF- κ B-dependent fashion (Fang et al., 1994; Lee et al., 2002; Marinari et al., 2004; Parry et al., 2005, 2003; Rogers et al., 2001).

Several ties have also been found between the intrinsic apoptotic pathway and autophagy, via Beclin-1 (a BCL-2 family-interacting protein that promotes autophagy) (Erlach et al., 2007). For example, it has been shown that mouse embryonic *Bax*^{-/-}*Bak*^{-/-} fibroblasts do not undergo apoptosis, but exhibit increased numbers of autophagosomes and autolysosomes, which can be blocked by knockdown of *Atg5* or *Atg6/Beclin-1* (Shimizu et al., 2004). Furthermore, the autophagy-inducing peptide Tat-Beclin-1 induces autophagic cell death in mammalian cells, which can be inhibited by inhibiting autophagy but not by inhibition of apoptosis or necroptosis (Liu et al., 2013). It has also been shown that Beclin-1 deficient T cells present increased susceptibility to apoptosis, at least in part, caused by the accumulation of the proapoptotic proteins BIM and caspases 3 and 8 (Kovacs et al., 2012). There is also further evidence of a crosstalk between autophagy and the intrinsic apoptotic pathway, via the interaction between ATG6/Beclin-1 and BCL-2 family members. During normal metabolic conditions, ATG6/Beclin-1 is sequestered by anti-apoptotic BCL-2 family members (e.g. BCL-2, BCL-XL, or MCL-1) through its BH3-like domain (Elgendy et al., 2011; Maiuri et al., 2007; Pattingre et al., 2005). This sequestration can be displaced by the BH3-only proteins, due to higher binding affinity to the anti-apoptotic proteins, which frees Atg6/Beclin-1 to initiate autophagy and caspase-independent autophagic cell death (Elgendy et al., 2011). Additionally, ATG5 and ATG6/Beclin-1 can also be cleaved by caspases and calpains, respectively, converting them into pro-apoptotic proteins that mediate mitochondrial cytochrome c release (Wirawan et al., 2010; Yousefi et al., 2006).

The extrinsic apoptotic pathway—Extrinsic apoptosis is triggered by transmembrane death receptors (DRs), which are members of the tumour necrosis receptor superfamily (TNFRSF). These include FAS/CD95, TNFR-1, DR3, DR4/TRAILR1 and DR5/TRAILR2, and all harbour a specific signalling motif in their cytoplasmic domain, called “death domain” (Galluzzi et al., 2018; Locksley et al., 2001). Upon binding of their respective ligands (death ligands), the receptors undergo trimerization, initiating receptor clustering and recruitment of adapter proteins (e.g. Fas-associated protein with death domain, FADD) to the death domain, forming a death-inducing signalling complex (DISC) (Ashkenazi and Dixit, 1999; Kischkel et al., 1995; Laster et al., 1988). Initiator caspases (e.g. caspase 8 and caspase 10) are then recruited to the DISC via their death effector domains (DEDs) or caspase recruitment domains (CARDs), and subsequently undergo cleavage into their mature, active form (Boldin et al., 1996; Chun et al., 2002; Kischkel et al., 1995; Li et al., 1997; Muzio et al., 1996; Wang et al., 1999; Yang et al., 1998). These initiator caspases can then cleave downstream effector caspases (i.e. caspase 3, caspase 6 and caspase 7) that

dismantle the cell (Li et al., 1997). However, in the presence of caspase inhibitors, the mechanism of cell death shifts from apoptosis to necroptosis (Vandenabeele et al., 2010).

Although the intrinsic pathway plays a more substantial role in controlling normal T-cell homeostasis, the extrinsic pathway also contributes. Death by neglect and negative selection seem to mainly be regulated via intrinsic apoptosis (with BIM as an integral activator), and mice expressing a dominant-negative construct of FADD show normal deletion of autoreactive thymocytes (Kotzin et al., 1988; Newton et al., 1998; Palmer, 2003). However, there have been reports of the extrinsic apoptotic pathway improving the efficacy of negative selection, in cases of high antigen-concentration (Kishimoto et al., 1998; Sprent and Kishimoto, 2002), and one report has showed defective negative selection and accelerated autoimmune disease in *Trail*^{-/-} mice, possibly owing to a loss of JNK activation (Green, 2003; Lamhamedi-Cherradi et al., 2003). In the periphery, FAS has been shown to be upregulated during activation, but also in malignancies, and has an important role in T cell homeostasis (Itoh et al., 1991; Trauth et al., 1989; Yonehara et al., 1989; Zheng et al., 1998). FAS has also recently been identified as a regulator of the balance between different subsets of CD4⁺ T cells (Meyer zu Horste et al., 2018; Yosef et al., 2013), preventing autoimmune tissue inflammation in normal physiological settings (Korn et al., 2009). Furthermore, the essential components of FAS-mediated DISC formation are constitutively expressed in both resting and activated T cells (Zheng et al., 1998). TCR-stimulation in T cell hybridomas or activated non-transformed T cells has been shown to induce FAS ligand and TNF expression, leading to FAS ligand binding by FAS and/or TNF binding by TNFR-1, and inducing apoptosis in an autocrine manner (Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995; Yang et al., 1995; Zheng et al., 1995). Furthermore, the identification of mutations in FAS and FAS ligand genes in patients with autoimmune lymphoproliferative syndrome (ALPS) also demonstrate the importance of FAS-mediated cell death in T cell homeostasis (Price et al., 2014). ALPS, a genetic disease signified by accumulation of high numbers of lymphocytes in the lymph nodes, liver and spleen, shows a similar altered immune homeostasis phenotype to mice with FAS and FAS ligand deficiencies (Zheng et al., 2017).

Crosstalk between the intrinsic and extrinsic pathways—In some T cells, signalling via the extrinsic apoptotic pathway is sufficient to induce apoptosis. These are known as type-I cells, and comprise e.g. long-term activated and proliferating T cells (Scaffidi et al., 1999). A second type (called type-II cells) do not generate sufficient caspase activation from DR signalling alone, but require amplification of the apoptotic signal (Scaffidi et al., 1998). This can be achieved via a mitochondrial amplification loop, which is initiated on top of DISC-mediated caspase activation via cleavage and activation of BH3-only protein BID, which triggers MOMP and activation of the intrinsic apoptotic pathway (Green et al., 1998; Wang, 2001). This ensures that the cellular commitment to apoptotic cell death is irreversible. T cells, shortly after activation and prior to proliferation, appear to be type-II cells, owing to inefficient DISC formation after FAS stimulation due to lower constitutive expression of the essential DISC components (Scaffidi et al., 1999; Zheng et al., 1998). Amplification of apoptotic signal has also been reported to function via caspase 3/7-mediated induction of MOMP after activation of the extrinsic apoptotic pathway, although this process seems to be non-essential in thymocyte development (Lakhani et al., 2006).

Thymocyte maturation and selection—T cells originate from haematopoietic stem cells which are formed in the bone marrow or foetal liver (Gale, 1987; Takaba and Takayanagi, 2017). Haematopoietic progenitor cells then migrate to the cortex of the thymus, and are expanded into immature thymocytes (lacking CD4, CD8), which (in the majority of cases) are developed into double-positive ($CD4^+$, $CD8^+$) thymocytes (Figure 1). T-cell antigen receptors (TCRs) are generated by DNA rearrangement, and positively selected in the thymic cortex for their capacity to recognise and bind host major histocompatibility complex (MHC) molecules expressed on cortical thymic epithelial cells (Takaba and Takayanagi, 2017). Double -positive thymocytes that are able to recognise MHC receive critical survival signals (e.g. DLL4 and IL7) from the cortical thymic epithelial cells, as well as signals to differentiate into $CD4^+$ (e.g. cathepsin L and TSSP) or $CD8^+$ (e.g. PSB11), single-positive T cells (Anderson and Takahama, 2012; Murata et al., 2007; Takada and Takahama, 2015; Takahama et al., 2012). Thymocytes showing no affinity for MHC do not receive the survival signals, and so are eliminated via apoptosis, a process called “death by neglect”. In this context, the intrinsic apoptotic pathway has been found to be of major importance. Glucocorticoid hormones have been known for a long time to induce apoptosis in immature thymocytes (Wyllie, 1980), and studies have shown that disrupting BCL-2 in mice enhances dexamethasone-induced thymocyte apoptosis (Veis et al., 1993), a process that is prevented by lack of BAX and BAK (Rathmell et al., 2002). Additionally, the interaction between D4 (the mouse homologue of CD99) and its ligand PILR (paired immunoglobulin-like type 2 receptor), which is located in the surface of thymic epithelial cells, has been proposed as a mechanism to regulate death by neglect in a caspase-8 dependent manner (Park et al., 2010; Salmena et al., 2003).

Positively selected $CD4^+$ or $CD8^+$ T cells express the chemokine receptor CCR7 and migrate into the medulla, where CCL19 and CCL21 (CCR7 ligands) are highly expressed (Förster et al., 2008). Here, the T cells interact with self-antigen-presenting cells, such as bone marrow-derived thymic dendritic cells (DCs) or medullary thymic epithelial cells, resulting in the deletion of autoreactive cells (Klein et al., 2014; Perry and Hsieh, 2016). Upon binding to self-MHC in the medulla with an unacceptably high affinity, apoptosis again results, a process called negative selection. The negative selection functions via the TCR signalling, involving MAPK pathways (including p38 and JNK) and seems to be dependent on the length of time for which MHC is bound, which affects the timing of activation for the different MAPKs (Mariathasan et al., 2001; Rincón et al., 1998; Sabapathy et al., 2001; Sugawara et al., 1998; Werlen et al., 2003, 2000). Although most autoreactive $CD4^+$ T cells are negatively eliminated in the medulla, a portion of them differentiate into regulatory T cells, characterized by expression of FOXP3, and specialize in the control of peripheral immune tolerance (Sakaguchi, 2000). Additional research into the mechanisms involved in T cell death during negative selection is needed, as loss of BIM and/or overexpression of BCL-2 rarely results in autoimmunity in mice on the C57BL/6J background (Hu et al., 2009; Kovalovsky et al., 2010; Linette et al., 1995; Sentman et al., 1991; Suen and Baldwin, 2012). Studies also suggest that caspases 3 and 7 are not necessary for positive and negative selection of thymocytes (Lakhani et al., 2006). However, BIM deficiency, abrogation of CD28/B7 costimulation, or BCL-2 transgenic overexpression, has been reported to increase the proportion of nonconventional fates, such as regulatory T cells,

anergic phenotype CD4⁺ T cells, and postselection double-negative thymocytes (Burger et al., 2014; Pobezinsky et al., 2012; Stritesky et al., 2013).

Necroptosis

Necroptosis, also known as programmed necrosis, is a cell death mechanism that is morphologically similar to necrosis (which is generally considered unregulated and occurs from tissue trauma) (Majno and Joris, 1995), but is regulated via a cellular signalling cascade (Galluzzi et al., 2018; Holler et al., 2000). These types of cell death are characterised by swelling of organelles and an increase in cell volume. This is followed by lysis and disintegration of the plasma membrane (Berghe et al., 2014; Linkermann and Green, 2014; Schweichel and Merker, 1973). Contrary to apoptosis, which is generally considered an immunogenically silent mode of cell elimination, necroptosis is a pro-inflammatory process which leads to release of danger-associated molecular patterns (DAMPs) (Kaczmarek et al., 2013; Proskuryakov et al., 2003). Necroptosis can be induced upon stimulation of Toll-like receptors 3 and 4 in the presence of caspase inhibitors, as well as the DNA-dependent activator of interferon-regulatory factors (DAI), but can also be mediated by DR ligation in certain contexts (Holler et al., 2000; Ma et al., 2005; Upton et al., 2012). In most contexts (i.e. Toll-like receptors 3 and 4, DAI and TNFR-1), receptor stimulation does not always lead to cell death, but instead induces inflammation even though the cell survives (Li et al., 2017b). Necroptotic activation in these cases is dependent on Receptor Interacting Serine/Threonine Kinase (RIPK) 1 and 3 (Cho et al., 2009; He et al., 2009; Holler et al., 2000; Zhang et al., 2009). For example, TNF binding to TNFR-1 can result in the formation of a protein complex (complex 1) consisting of e.g. TNFR-1-associated DD protein (TRADD), RIPK1 and cellular inhibitor of apoptosis protein (cIAP) 1 or 2. This complex induces a signalling cascade that activates NF- κ B and AP-1, which results in pro-inflammatory signals (Hsu et al., 1996; Micheau and Tschopp, 2003). This is dependent on the integrity of complex 1, however, and if destabilised, TRADD instead binds FADD and caspase 8, and forms complex 2a (Micheau and Tschopp, 2003). Complex 2a promotes apoptosis through caspase 8, and represses necroptosis by cleavage of RIPK1 and 3 (Feng et al., 2007; Lin et al., 1999; Oberst et al., 2011). When cIAP1 or 2 are inhibited, complex 2b is instead formed, consisting of RIPK1, RIPK3, FADD, cFLIP, and caspase 8, which subsequently form a large amyloid-like structure called a necrosome (Cho et al., 2009; He et al., 2009; Li et al., 2012). The necrosome is instrumental in the phosphorylation of mixed lineage kinase domain-like protein (MLKL) which then oligomerises, translocates to the cell membrane, and mediates membrane permeabilization (Sun et al., 2012; Zhao et al., 2012). This results in death of the cell and release of DAMPs into the extracellular space (Cai et al., 2014; Chen et al., 2014; Dondelinger et al., 2014; Murphy et al., 2013; Su et al., 2014; Wang et al., 2014). These DAMPs can then activate Toll-like and other receptors on surrounding cells, leading to a further increased inflammatory response (Li et al., 2017b). In T cells, necroptosis appears to function as an alternative, backup mechanism to apoptosis, to be activated in case of inhibition of caspase 8 by viral infection (Mocarski et al., 2012; Weinlich et al., 2011). Data has shown that deletion of caspase 8 in T cells in *Bim*^{-/-} mice is able to suppress autoimmunity via necroptotic cell death of autoreactive T cells (Bohgaki et al., 2011). The role of necroptosis in T cells under normal physiological conditions is, however, still not clear. Although loss of caspase 8 function is not commonly observed in

normally functioning human cells, an inhibitor of caspase 8 encoded by human cytomegalovirus has been suggested to influence the DC-mediated activation of T cells, by stimulating a more profound release of DAMPs from dying cells (Martin et al., 2008; Skaletskaya et al., 2001). Human cytomegalovirus also blocks necroptosis downstream of MLKL via an unknown mechanism (Mocarski et al., 2012).

Pyroptosis

Pyroptosis is a highly inflammatory form of programmed necrosis, mediated by one or more of the inflammatory caspases (caspase 1, 4, and 5 in humans; caspase 1 and 11 in mice) (Brennan and Cookson, 2000; Case et al., 2013; Fink and Cookson, 2006). It is initiated following inflammasome activation and shares morphological characteristics with necroptosis, such as cell swelling, rupture of the cell membrane, and release of DAMPs and pro-inflammatory cytokines (e.g. IL-1 β and IL-18) (Cookson and Brennan, 2001; Fink and Cookson, 2006; Watson et al., 2000). The inflammasome is a multiprotein oligomer which promotes the cleavage and activation of pro-caspase 1, which then processes IL-1 β and IL-18 into their mature forms (Martinon et al., 2002). Inflammasome activation can be induced by a variety of cellular stress factors, including recognition of molecular patterns expressed by invading pathogens. These patterns are monitored by pattern recognition receptors, which can detect threats both extracellularly (via e.g. Toll-like receptors or C-type Lectin Receptors) or intracellularly (via e.g. Nod-like receptors and RIG-I-like receptors) (Martinon et al., 2002; Srinivasula et al., 2002; Tschopp et al., 2003). Once activated, the inflammasome can trigger cleavage of gasdermin D, the downstream effector of pyroptosis, which then translocates to the cell membrane and forms pores by binding to phosphatidylinositides and oligomerizing (Aglietti et al., 2016; Ding et al., 2016; Liu et al., 2016; Sborgi et al., 2016; Shi et al., 2015). This typically causes membrane disruption and cell lysis, however, recent reports have shown that gasdermin D pore formation is needed for IL1 β secretion from inflammasome-activated macrophages without, at least initially, compromising the viability of the macrophage (Evavold et al., 2017). Pyroptosis is an important factor in antimicrobial response, since the consequential amplification of the host immune defence leads to rapid clearance of infected cells, thereby depriving the pathogen of its replicative niche (Aachoui et al., 2013; Galluzzi et al., 2018). However, this defence mechanism may be disadvantageous for T cells in some cases. For example, In HIV-infected hosts, CD4 $^{+}$ T cells are eliminated due to abortive HIV infection. In this process, viral DNA transcripts accumulate in the cytosol, which can result in inflammasome assembly and pyroptosis (Monroe et al., 2014). This in turn leads to DAMP and cytokine release which creates further inflammation, feeding further inflammation and pyroptosis in surrounding cells and even more loss of CD4 $^{+}$ T cells (Doitsh et al., 2014, 2010). Further research is needed to elucidate the role of pyroptosis in other T cell subsets.

Ferroptosis

Ferroptosis is a recently recognized form of regulated cell death, characterised by morphological changes such as unusually small mitochondria, condensed mitochondrial membrane densities, reduction of mitochondrial inner membrane folds (cristae), and rupture of the outer mitochondrial membrane (Dixon et al., 2012). Ferroptosis is driven by loss of activity of the lipid repair enzyme glutathione peroxidase 4 (GPX4), leading to accumulation

of lipid-based reactive oxygen species (Yang and Stockwell, 2016). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. Although relatively few studies have been performed to date, a role for this cell death process in several biological processes is beginning to be revealed (Yang and Stockwell, 2016). For example, conditional deletion of *Gpx4* in T cells in mice has been shown to result in T cell ferroptosis, leading to lack of an immune response to infection and suggesting a role for GPX4 in T cell-mediated immunity (Matsushita et al., 2015).

T cell-mediated cell death

For the adaptive immune system to be activated, DCs first need to detect threat-associated antigens, as well as DAMPs which serve as adjuvant signals as a consequence of cellular stress and death (Farkas et al., 2007; Kaczmarek et al., 2013). Upon immune system detection of DAMPs, signalling the presence of potential threats such as pathogens or cancerous cells, immature CD8⁺ T cells are converted to cytotoxic CD8⁺ T cells (cT cells) (Hivroz et al., 2012). These cT cells express antigen-specific TCRs, which upon stimulation activate effector mechanisms (illustrated in Figure 2) to eliminate the cells from which the threat signal emanated. In order to maintain self-tolerance, the activity of the cT cells can be prevented by pathways known as immune checkpoints, which is imperative for maintaining homeostasis but can be detrimental to the effects of cancer immunotherapy (Pardoll, 2012). To circumvent these problems, checkpoint inhibitors (e.g. anti-CTLA4, anti-PD-1 and anti-PD-L1) have been developed and have shown durable clinical responses in a multitude of cancers (Sharma and Allison, 2015). This is accomplished via the granule exocytosis pathway (Bossi and Griffiths, 2005; De Saint Basile et al., 2010), and/or the expression and release of death ligands (Anel et al., 1994; Takeda et al., 2001). The following section details the mechanisms involved in these effector processes as well as the scenarios in which they are utilized.

Granule Exocytosis

The granule exocytosis pathway is rapidly executed after cT cells are exposed to infected/dysfunctional somatic cells. This is characterised by mobilisation of preformed, specialized cytoplasmic granules, containing the cytotoxins perforin (PRF1), granzymes, and granulysin (Chowdhury and Lieberman, 2008; Krensky and Clayberger, 2009; Milstein et al., 2011; Pardo et al., 2009; Voskoboinik et al., 2006). These granulocytes are released toward the contact site (immunological synapse) of the target infected/dysfunctional cell (Bossi and Griffiths, 2005; De Saint Basile et al., 2010). The delivery of the cytotoxins from the granules into the target cell is a matter of intense debate, and has only recently begun to be clarified. According to current knowledge, the pore-forming protein PRF1 forms pores in the plasma membrane upon degranulation, and acts as a vehicle to allow the granzymes to enter the cytosol (Lopez et al., 2013; Metkar et al., 2011; Voskoboinik et al., 2006). Although this mechanism has been observed in physiological conditions, it is still unclear whether the alternative hypothesised mechanisms may also operate in certain contexts. These proposed mechanisms include receptor- or clathrin-mediated granzyme and PRF1 co-endocytosis

followed by PRF1-mediated pore formation in the endosome and subsequent granzyme release (Pipkin and Lieberman, 2007). Additionally, in cases where there is a deficit of granzyme expression, it has been proposed that PRF1 can kill target cells by itself by means of cell lysis, a mechanism that has been demonstrated in rat basophil leukaemia cells transfected with PRF1 cDNA lyse Jurkat cells (Voskoboinik et al., 2004). It has also been shown that antigen-specific cT cells in granzyme knockout mice are able to induce cell death in tumour target cells, at a reduced level compared with WT mice (Hoves et al., 2011; Pardo et al., 2004; Simon et al., 1997; Torán et al., 2001). In these knockout mice, the cT cell-induced cell death does not involve caspase activation, eliminated cells are not efficiently phagocytosed by dendritic cells, and do not induce antigen cross-presentation (Hoves et al., 2011; Pardo et al., 2004; Waterhouse et al., 2006).

Granzymes are a family of serine proteases that are expressed in cT cells and NK cells (Ewen et al., 2012). In total, 5 different granzymes have been described in humans (granzyme A, B, C, H, K, and M), and 10 in mice (Bovenschen and Kummer, 2010; Pardo et al., 2009; Voskoboinik et al., 2015). Of these, Granzyme A and B have garnered the most attention. Several of these have been shown to induce cell death in vitro, and among them, only granzyme B does so via apoptosis (Bovenschen and Kummer, 2010; Chowdhury and Lieberman, 2008; Ewen et al., 2012). For example, granzyme A-induced cell death is characterized by phosphatidylserine exposure, chromatin condensation, single-stranded DNA nicking, and ROS production, and occurs without cleavage of caspases or involvement of the BCL-2 family proteins (Martinvalet et al., 2005). Current models suggests that granzyme A instead induces cell death via disruption of the ER-associated oxidative stress response SET complex via generation of reactive oxygen species (Martinvalet et al., 2008). Additionally, granzyme A has also been shown to regulate proinflammatory cytokine production (e.g. IL1b) in a caspase dependent manner, which may involve the infammasome (Metkar et al., 2008). Granzyme B, however, can induce apoptosis via the intrinsic pathway (Heibein et al., 1999; Pinkoski et al., 2001). This is orchestrated by proteolytic activation of BID at aspartate, resulting in its translocation to the mitochondrial membrane and activation of BAX and/or BAK (Barry et al., 2000; Hameed et al., 1988; Heibein et al., 2000; Sutton et al., 2000). Rather than result in cytochrome c release, however, this instead leads to release of inhibitor of apoptosis proteins (IAPs) and later of SMAC/DIABLO, which relieves IAP inhibition of autocatalytic caspase 3 maturation, allowing it to be cleaved (Goping et al., 2003; Sutton et al., 2003). Additionally, granzyme B is also able to cleave aspartic acid residues and directly activate caspases (e.g. caspase 3, 7, 8, and 10), inducing apoptosis without the need for MOMP (Ewen et al., 2012; Otake et al., 1991). Finally, granzyme B has also been reported to activate the mitochondrial pathway by disrupting MCL-1/BIM or BCL-XL complexes, allowing BIM to activate BAX and/or BAK (Catalán et al., 2015; Han et al., 2005, 2004). Concerning the remaining granzymes, they have been described to be able to induce cell death as well as regulate the production of proinflammatory cytokines, but the mechanisms are still unknown and the relevance of these granzymes during physiological conditions has been questioned (Anthony et al., 2010; Bovenschen and Kummer, 2010; Chowdhury and Lieberman, 2008; Ewen et al., 2012; Hoves et al., 2010; Joeckel and Bird, 2014; Pardo et al., 2009; Voskoboinik et al., 2015). At present, it is

unknown whether other mechanisms of cell death and/or survival such ferroptosis or autophagy-dependent cell death may regulate cell death executed by granzymes.

Death ligand secretion

A variety of different death ligands are expressed by cT cells, including TNF α , FAS ligand, and TRAIL. During cT-mediated cell death of target cells, these ligands are expressed at the cT cell membrane or secreted as exosome membrane-bound death ligands, and activate the extrinsic (and in some cases the intrinsic) apoptotic pathway in the target cell (Martínez-Lostao et al., 2015). The use of cT cell death ligand secretion is mainly involved in a process which is classically known as activation-induced cell death, now being redubbed as TCR restimulation-induced cell death (RICD) (Martínez-Lostao et al., 2015; Zheng et al., 2017). RICD is one of the mechanisms responsible for regulating peripheral immune tolerance, and functions via FAS-mediated extrinsic apoptosis (Krammer et al., 2007; Kuklina, 2013). Restimulation of TCR in cycling T cells leads to activation of RICD, dependent on the presence of T cell growth cytokines (e.g. IL2), creating a feedback mechanism called propioidical regulation in which IL2-stimulated proliferation serves an indicator of excess T cell expansion (Lenardo et al., 1999; Lenardo, 1991; Zheng et al., 1998). The reactivation also leads to FAS ligand and TRAIL de novo synthesis in the cT cell, which in turn leads to increasing formation of death ligand exosomes and death ligand surface expression (Martínez-Lostao et al., 2015).

While FAS has been shown to be ubiquitously expressed in different tissues, the FAS ligand is restricted to T cells, particularly cT cells (Krammer, 2000; Suda et al., 1993), and cT cell FAS ligand secretion has also been reported to be involved in the removal of viruses that express FAS .

Immunosurveillance

Peripheral T cells constantly monitor our bodies for signs of pathogens or cancerous cells. This process involves not only detection but also rapid elimination of potential threats. In terms of cancer immunosurveillance, most evidence indicate that PRF1 (and consequently granule exocytosis) is a key factor for cT cell-mediated control of tumours, both during carcinogenesis and metastasis, especially for tumours of haematological origin (Bolitho et al., 2007; Kägi et al., 1994a; Pardo et al., 2002; M J Smyth et al., 2000; Smyth et al., 1999; Torán et al., 2001; Trapani et al., 2013; van den Broek et al., 1996). Additionally, deficiency in PRF1 has been shown to enhance the oncogenic potential of several different proteins such as ABL1, BCL-2 and MLH1 (Bolitho et al., 2009), as well as accelerate the onset and neoplastic grade of HER2/neu-driven ductal carcinoma (Macagno et al., 2014; Street et al., 2007).

The role of granzymes in immunosurveillance is much less clear, with different reports from granzyme A and B-deficient mice showing either higher tumour formation potential or no difference, compared with WT mice for several different cancer cell lines (Fehniger et al., 2007; Pardo et al., 2002; Revell et al., 2005; Smyth et al., 2003; Torán et al., 2001). Deficiency in other granzymes does not seem to have an effect on tumour formation, which may be due to their relatively weaker cytotoxic potential (Joeckel et al., 2011; Pao et al.,

2005). It is possible that in some cases of granzyme deficiency, the alternative target cell elimination mechanism via PRF1 cell lysis may compensate and thus maintain tumour control (Voskoboinik et al., 2006).

It has also been shown that death ligand secretion may contribute to tumour immunosurveillance. For example, PRF1-deficient cT cells have been shown to induce cell death in tumour cells in vivo via FAS activation (Afshar-Sterle et al., 2014; Kägi et al., 1994b; Lowin et al., 1994), and TRAIL-mediated extrinsic apoptosis is generally considered to also play a role in cancer immunosurveillance (Cretney et al., 2002; Grosse-Wilde et al., 2008; Smyth et al., 2001; Takeda et al., 2002, 2001). Mutations in FAS and/or FAS ligand has also been correlated with higher incidence of B and T lymphoma, both in animal models and in humans (Afshar-Sterle et al., 2014; Davidson et al., 1998; Peng et al., 1996; Price et al., 2014; Straus et al., 2001). No such results have been reported regarding TRAIL/DR mutations. In light of results showing that tumor cells which are resistant to extrinsic apoptosis may instead die via necroptosis following DR or FAS activation, the added immunogenicity of this cell death mode may have an impact on immunosurveillance. This may offer an explanation for reports showing that tumour cells can use TRAIL or Fas ligand to promote invasiveness and development of metastases (Azijli et al., 2013; Barnhart et al., 2004; Trauzold et al., 2006; von Karstedt et al., 2015).

Cancer immunotherapy

Cancer immunotherapy has gained a lot of momentum in recent years, largely due to the development of checkpoint inhibitors such as anti-CTLA4 and anti-PD1. In these scenarios, cytotoxic lymphocytes (mainly cT cells and natural killer cells) perform the killing of cancer cells. The involvement of granule exocytosis in this killing has not been thoroughly explored, and results from the studies that have been performed are not easily interpreted (Allard et al., 2013; Seki et al., 2002; Sin et al., 2012). Studies using the immunodominant cT cell epitope, lymphocytic choriomeningitis virus (LCMV) peptide gp33, to activate virus-specific cT cell responses have shown a dependence upon PRF1, but not FAS ligand (Martínez-Lostao et al., 2015). Additionally, PRF1 was shown to contribute significantly to the antitumoral effect of the combination of BRAF inhibitors and agonistic anti-CD137 antibody in melanoma cells (Knight et al., 2013), and anti-CD137-mediated killing of lymphoma cells in mice has been shown to be dependent on both PRF1 and FAS ligand (Morales-Kastresana et al., 2013). In contrast, PRF1-deficiency did not have an effect on the in vivo efficacy of anti-CD73, anti-CTLA-4, anti-PD-1 therapy in colon, prostate, and breast carcinoma cell lines (Allard et al., 2013). Similar discrepancies in PRF1-dependency have also been reported regarding IL12-mediated tumour control (Hashimoto et al., 1999; Hayakawa et al., 2001; Kodama et al., 1999; Liu et al., 2012; Schultz et al., 1999; Sin et al., 2012; Song et al., 2000), suggesting that the mechanisms may be dependent on model and/or tumour type (Mark J Smyth et al., 2000).

Concerning the involvement of death ligand secretion in cancer immunotherapy, a similarly complex image is portrayed. FAS ligand has been shown to be involved in IL18-mediated elimination of B16 melanoma cells (Morales-Kastresana et al., 2013), but neither FAS ligand or TRAIL were instrumental in the anti-tumour effect in other melanoma models

using combination therapy with BRAF-inhibitors and agonistic antiCD137 antibody (Knight et al., 2013). TRAIL inhibition has, however, been shown to block IL12 and α -Galactosylceramide-mediated control of liver metastases in a renal carcinoma model (Smyth et al., 2001). In all, these studies indicate that the mechanisms involved in cT cell-mediated cell death differ between the contexts of immunosurveillance and immunotherapy. This is supported by studies analysing both contexts in the same models, which show that mice deficient in granzyme B do not exhibit a higher susceptibility than WT mice to 3-methylcholanthrene-induced sarcomas (Torán et al., 2001), but fail to control implanted sarcomas during adoptive NK-cell transfer (Pegram et al., 2010). Additionally, PRF1-deficient mice show an increased susceptibility to forming tumours when implanted with the prostate cancer cell line RM1 (Smyth et al., 1999), but do not show a difference in tumour control after treatment with BRAF-inhibitors and agonistic anti-CD137 antibody (Knight et al., 2013), compared with WT mice. PRF1-deficiency also results in higher susceptibility to implanted or oncogene-driven breast carcinoma than WT mice, but does not hamper the control of implanted breast carcinoma during treatment with checkpoint inhibitors (Allard et al., 2013; Macagno et al., 2014; Smyth et al., 1999; Street et al., 2007). Finally, mice with PRF1-deficiency also have increased metastatic susceptibility in renal cancer (Abdool et al., 2006), but this has no effect on metastasis control during IL12/ α -Galactosylceramide or adoptive cT cell therapy (Seki et al., 2002; Smyth et al., 2001). These differences may potentially be explained by differences in the amplitude of stimuli that are recognized by cT or NK cells (Shanker et al., 2009).

Concluding remarks

Both in terms of T cell death and T cell-mediated killing, apoptosis is the primary method of elimination in developmental and homeostatic regulation. This involves mainly the intrinsic pathway (via modulation of BIM) but can also be executed via the extrinsic pathway. In the culling of unwanted T cells, other cell death pathways such as pyroptosis, necroptosis, and ferroptosis seem to function mainly as backup mechanisms which come into play only under specific conditions in which the apoptotic pathways are unavailable. Regarding cT cell-mediated killing, the effector mechanisms seem to differ depending on whether the cell is performing immunosurveillance or is involved in a cancer immunotherapeutic setting. In the context of cancer immunotherapy, granule exocytosis and activation of the intrinsic apoptotic pathway via PRF1 and granzyme B seems to be the most potent killing mechanism, and is even able to achieve commitment to cell death in case of target cell apoptosis deficiency (such as p53 deletion/mutation, overexpression of pro-survival BCL-2 family members, or caspase inhibition). More research is needed to elucidate the mechanisms and physiological relevance of other granzymes concerning the induction of cell death. This may be of value in predicting patient responses to e.g. cancer immunotherapy, both in terms of the efficacy of the treatment to kill the target cell, but also in terms of avoiding undesirable toxicities.

Acknowledgements:

We gratefully acknowledge funding from the Sweden-America Foundation (J.S.), Alex's Lemonade Stand Foundation for Childhood Cancers Young Investigator Award (K.A.S.), Andrew McDonough B+ Foundation

Childhood Cancer Research Grant (K.A.S.), Harvard T.H. Chan School of Public Health Dean's Fund for Scientific Advancement (K.A.S.) as well as NIH/NCI grant R00CA188679 (K.A.S.).

References

- Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE, Tan MH, Cotter PA, Vance RE, Aderem A, Miao EA, 2013 Caspase-11 protects against bacteria that escape the vacuole. *Science* (80-.). 339, 975–978. 10.1126/science.1230751
- Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW Jr., Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ, 2006 NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. *J Immunol* 177, 2575–2583. <https://doi.org/10.1093/immk/177/4/2575> [pii] [PubMed: 16888019]
- Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, Rödling L, Alsop AE, Walker J, Masson F, Belz GT, Corcoran LM, O'reilly LA, Strasser A, Smyth MJ, Johnstone R, Tarlinton DM, Nutt SL, Kallies A, 2014 Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. *Nat. Med* 20, 283–290. 10.1038/nm.3442 [PubMed: 24487434]
- Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS, Kayagaki N, Ciferri C, Dixit VM, Dueber EC, 2016 GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. *Proc. Natl. Acad. Sci* 113, 7858–7863. 10.1073/pnas.1607769113 [PubMed: 27339137]
- Allard B, Pommey S, Smyth MJ, Stagg J, 2013 Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. *Clin. Cancer Res.* 19, 5626–5635. 10.1158/1078-0432.CCR-13-0545 [PubMed: 23983257]
- Anaya J-M, Shoenfeld Y, Rojas-Villarraga A, Levy RA, Cervera R, 2013 Autoimmunity, Autoimmunity: From Bench to Bedside.
- Anderson G, Takahama Y, 2012 Thymic epithelial cells: Working class heroes for T cell development and repertoire selection. *Trends Immunol.* 10.1016/j.it.2012.03.005
- Anel A, Buferne M, Boyer C, Schmitt-Verhulst AM, Golstein P, 1994 T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. *Eur. J. Immunol* 24, 2469–2476. 10.1002/eji.1830241032 [PubMed: 7523141]
- Anthony DA, Andrews DM, Chow M, Watt SV, House C, Akira S, Bird PI, Trapani JA, Smyth MJ, 2010 A Role for Granzyme M in TLR4-Driven Inflammation and Endotoxemia. *J. Immunol* 185, 1794–1803. 10.4049/jimmunol.1000430 [PubMed: 20585036]
- Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N, 2014 Mechanism of activation-induced cell death of T cells and regulation of FasL expression. *Crit. Rev. Immunol* 34, 301–14. 10.1615/CritRevImmunol.2014009988 [PubMed: 24941158]
- Ardoin SP, Pisetsky DS, 2008 The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. *Mod. Rheumatol* 10.1007/s10165-008-0054-z
- Ashkenazi A, Dixit VM, 1999 Apoptosis control by death and decoy receptors. *Curr. Opin. Cell Biol.* 10.1016/S0955-0674(99)80034-9
- Azizli K, Weyhenmeyer B, Peters GJ, De Jong S, Krut FAE, 2013 Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: Discord in the death receptor family. *Cell Death Differ.* 10.1038/cdd.2013.28
- Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME, 2004 CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. *EMBO J.* 23, 3175–3185. 10.1038/sj.emboj.7600325 [PubMed: 15272306]
- Barry M, Heibei J. a, Pinkoski MJ, Lee SF, Moyer RW, Green DR, Bleackley RC, 2000 Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. *Mol. Cell. Biol* 20, 3781–3794. 10.1128/MCB.20.11.3781-3794.2000 [PubMed: 10805722]
- Berghe T Vanden, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P, 2014 Regulated necrosis: The expanding network of non-apoptotic cell death pathways. *Nat. Rev. Mol. Cell Biol.* 10.1038/nrm3737

- Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St. Clair EW, Turka LA, 2010 The Immune Tolerance Network at 10 years: Tolerance research at the bedside. *Nat. Rev. Immunol* 10.1038/nri2869
- Bohgaki T, Mozo J, Salmena L, Matysiak-Zablocki E, Bohgaki M, Sanchez O, Strasser A, Hakem A, Hakem R, 2011 Caspase-8 inactivation in T cells increases necroptosis and suppresses autoimmunity in Bim^{-/-} mice. *J. Cell Biol.* 195, 277–291. 10.1083/jcb.201103053 [PubMed: 22006951]
- Boldin MP, Goncharov TM, Goltsev YV, Wallach D, 1996 Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell* 85, 803–815. 10.1016/S0092-8674(00)81265-9 [PubMed: 8681376]
- Bolitho P, Street SEA, Westwood JA, Edelmann W, Macgregor D, Waring P, Murray WK, Godfrey DI, Trapani JA, Johnstone RW, Smyth MJ, 2009 Perforin-mediated suppression of B-cell lymphoma. *Proc. Natl. Acad. Sci. U. S. A* 106, 2723–8. 10.1073/pnas.0809008106 [PubMed: 19196996]
- Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ, 2007 Apoptosis induced by the lymphocyte effector molecule perforin. *Curr. Opin. Immunol* 10.1016/j.coi.2007.04.007
- Bossi G, Griffiths GM, 2005 CTL secretory lysosomes: Biogenesis and secretion of a harmful organelle. *Semin. Immunol* 10.1016/j.smim.2004.09.007
- Bouillet P, Metcalf D, Huang DCS, 1999 Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. *Science* (80-.). 286, 1735–1738. 10.1126/science.286.5445.1735
- Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, Pellegrini M, Cory S, Adams JM, Strasser A, 2002 BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. *Nature* 415, 922–926. 10.1038/415922a [PubMed: 11859372]
- Bovenschen N, Kummer JA, 2010 Orphan granzymes find a home. *Immunol. Rev* 10.1111/j.0105-2896.2010.00889.x
- Brennan MA, Cookson BT, 2000 Salmonella induces macrophage death by caspase-1-dependent necrosis. *Mol. Microbiol* 38, 31–40. 10.1046/j.1365-2958.2000.02103.x [PubMed: 11029688]
- Brunner T, Mogil RJ, LaFace D, Jin Yoo N, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR, 1995 Cell-autonomous fas (CD95)/fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. *Nature* 373, 441–444. 10.1038/373441a0 [PubMed: 7530336]
- Burger ML, Leung KK, Bennett MJ, Winoto A, 2014 T cell-specific inhibition of multiple apoptotic pathways blocks negative selection and causes autoimmunity. *Elife*. 10.7554/eLife.03468
- Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J, Ward Y, Wu LG, Liu ZG, 2014 Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. *Nat. Cell Biol.* 16, 55–65. 10.1038/ncb2883 [PubMed: 24316671]
- Case CL, Kohler LJ, Lima JB, Strowig T, de Zoete MR, Flavell RA, Zamboni DS, Roy CR, 2013 Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to *Legionella pneumophila*. *Proc. Natl. Acad. Sci* 110, 1851–1856. 10.1073/pnas.1211521110 [PubMed: 23307811]
- Catalán E, Jaime-Sánchez P, Aguilo N, Simon MM, Froelich CJ, Pardo J, 2015 Mouse cytotoxic T cell-derived granzyme B activates the mitochondrial cell death pathway in a bim-dependent fashion. *J. Biol. Chem* 290, 6868–6877. 10.1074/jbc.M114.631564 [PubMed: 25605735]
- Chen X, Li W, Ren J, Huang D, He WT, Song Y, Yang C, Li W, Zheng X, Chen P, Han J, 2014 Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. *Cell Res.* 24, 105–121. 10.1038/cr.2013.171 [PubMed: 24366341]
- Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FKM, 2009 Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation. *Cell* 137, 1112–1123. 10.1016/j.cell.2009.05.037 [PubMed: 19524513]
- Chowdhury D, Lieberman J, 2008 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death. *Annu. Rev. Immunol* 26, 389–420. 10.1146/annurev.immunol.26.021607.090404 [PubMed: 18304003]
- Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ, 2002 Pleiotropic defects in lymphocyte

- activation caused by caspase-8 mutations lead to human immunodeficiency. *Nature* 419, 395–399. 10.1038/nature01063 [PubMed: 12353035]
- Clayton LK, Ghendler Y, Mizoguchi E, Patch RJ, Ocain TD, Orth K, Bhan AK, Dixit VM, Reinherz EL, 1997 T-cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: The molecular basis of negative selection. *EMBO J.* 16, 2282–2293. 10.1093/emboj/16.9.2282 [PubMed: 9171343]
- Cookson BT, Brennan MA, 2001 Pro-inflammatory programmed cell death. *Trends Microbiol.* 9, 113–114. 10.1016/S0966-842X(00)01936-3 [PubMed: 11303500]
- Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ, 2002 Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice. *J. Immunol* 168, 1356–1361. 10.4049/jimmunol.168.3.1356 [PubMed: 11801676]
- Czabotar PE, Lessene G, Strasser A, Adams JM, 2014 Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. *Nat. Rev. Mol. Cell Biol.* 10.1038/nrm3722
- Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, Lee EF, Yao S, Robin AY, Smith BJ, Huang DCS, Kluck RM, Adams JM, Colman PM, 2013 Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. *Cell* 152, 519–531. 10.1016/j.cell.2012.12.031 [PubMed: 23374347]
- Danial NN, Korsmeyer SJ, 2004 Cell Death: Critical Control Points. *Cell* 116, 205–219. [PubMed: 14744432]
- Davidson WF, Giese T, Fredrickson TN, 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. *J. Exp. Med* 187, 1825–38. 10.1084/jem.187.11.1825
- De Saint Basile G, Ménasché G, Fischer A, 2010 Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. *Nat. Rev. Immunol* 10.1038/nri2803
- Dhein J, Walczak H, Bäumlert C, Debatint KM, Krammer PH, 1995 Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). *Nature* 373, 438–441. 10.1038/373438a0 [PubMed: 7530335]
- Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang DC, Shao F, 2016 Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature* 535, 111–116. 10.1038/nature18590 [PubMed: 27281216]
- Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR, 2012 Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell* 149, 1060–1072. 10.1016/j.cell.2012.03.042 [PubMed: 22632970]
- Doerflinger M, Glab JA, Puthalakath H, 2015 BH3-only proteins: A 20-year stock-take. *FEBS J.* 10.1111/febs.13190
- Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Greene WC, 2010 Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. *Cell* 143, 789–801. 10.1016/j.cell.2010.11.001 [PubMed: 21111238]
- Doitsh G, Galloway NLK, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC, 2014 Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. *Nature* 505, 509–514. 10.1038/nature12940 [PubMed: 24356306]
- Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, Hulpiau P, Weber K, Sehon CA, Marquis RW, Bertin J, Gough PJ, Savvides S, Martinou JC, Bertrand MJM, Vandenabeele P, 2014 MLKL Compromises Plasma Membrane Integrity by Binding to Phosphatidylinositol Phosphates. *Cell Rep.* 7, 971–981. 10.1016/j.celrep.2014.04.026 [PubMed: 24813885]
- Dzhagalov I, Dunkle A, He Y-W, 2008 The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. *J. Immunol* 181, 521–8. 10.4049/jimmunol.181.1.521 [PubMed: 18566418]
- Elgendy M, Sheridan C, Brumatti G, Martin SJ, 2011 Oncogenic Ras-Induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival. *Mol. Cell* 42, 23–35. 10.1016/j.molcel.2011.02.009 [PubMed: 21353614]
- Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A, 2003 Loss of the Pro-Apoptotic BH3-only Bcl-2 Family Member Bim Inhibits BCR Stimulation-induced Apoptosis and Deletion

- of Autoreactive B Cells. *J. Exp. Med* 198, 1119–1126. 10.1084/jem.20030411 [PubMed: 14517273]
- Erlich S, Mizrachy L, Segev O, Lindenboim L, Zmira O, Adi-Harel S, Hirsch JA, Stein R, Pinkas-Kramarski R, 2007 Differential interactions between Beclin 1 and Bcl-2 family members. *Autophagy*. 10.4161/auto.4713
- Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC, 2017 The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. *Immunity*. 10.1016/j.immuni.2017.11.013
- Ewen CL, Kane KP, Bleackley RC, 2012 A quarter century of granzymes. *Cell Death Differ*. 10.1038/cdd.2011.153
- Fang W, Rivard JJ, Mueller DL, Behrens TW, 1994 Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes. *J Immunol* 153, 4388–4398. [PubMed: 7963517]
- Farkas AM, Kilgore TM, Lotze MT, 2007 Detecting DNA : Getting and begetting cancer. *Curr. Opin. Investig. Drugs* 8.
- Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French ARR, Ley TJ, 2007 Acquisition of Murine NK Cell Cytotoxicity Requires the Translation of a Pre-existing Pool of Granzyme B and Perforin mRNAs. *Immunity* 26, 798–811. 10.1016/j.immuni.2007.04.010 [PubMed: 17540585]
- Feng S, Yang Y, Mei Y, Ma L, Zhu D. e., Hoti N, Castanares M, Wu M, 2007 Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. *Cell. Signal* 19, 2056–2067. 10.1016/j.cellsig.2007.05.016 [PubMed: 17644308]
- Fink SL, Cookson BT, 2006 Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. *Cell. Microbiol* 8, 1812–1825. 10.1111/j.1462-5822.2006.00751.x [PubMed: 16824040]
- Fischer SF, Belz GT, Strasser A, 2008 BH3-only protein Puma contributes to death of antigen-specific T cells during shutdown of an immune response to acute viral infection. *Proc. Natl. Acad. Sci. U. S. A* 105, 3035–40. 10.1073/pnas.0706913105 [PubMed: 18287039]
- Förster R, Davalos-Misslitz AC, Rot A, 2008 CCR7 and its ligands: Balancing immunity and tolerance. *Nat. Rev. Immunol* 10.1038/nri2297
- Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, Shen H, 2002 Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. *J Immunol* 168, 1528–1532. [PubMed: 11823476]
- Fuchs Y, Steller H, 2011 Programmed cell death in animal development and disease. *Cell*. 10.1016/j.cell.2011.10.033
- Gale RP, 1987 Development of the immune system in human fetal liver. *Thymus* 10, 45–56. [PubMed: 3324404]
- Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malorni W, Marine JCW, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JHM, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G, 2009 Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. *Cell Death Differ*. 10.1038/cdd.2009.44
- Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G, 2017 Immunogenic cell death in cancer and infectious disease. *Nat. Rev. Immunol* 10.1038/nri.2016.107
- Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK-M, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M,

Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin K-M, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine J-C, Martin SJ, Martinou J-C, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon H-U, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G, 2018 Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ.* 10.1038/s41418-017-0012-4

- Glab JA, Mbogo GW, Puthalakath H, 2017 BH3-Only Proteins in Health and Disease, International Review of Cell and Molecular Biology. Elsevier Inc 10.1016/bs.ircmb.2016.08.005
- Golav B, 2011 Apoptosis in polycystic kidney disease. *Biochim. Biophys. Acta* 1812, 1272–1280. 10.1016/j.bbdis.2011.01.006 [PubMed: 21241798]
- Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM, Shostak I, Roberts DL, Hunter AM, Korneluk R, Bleackley RC, 2003 Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. *Immunity* 18, 355–365. 10.1016/S1074-7613(03)00032-3 [PubMed: 12648453]
- Gray DHD, Kupresanin F, Berzins SP, Herold MJ, O'Reilly LA, Bouillet P, Strasser A, 2012 The BH3-Only Proteins Bim and Puma Cooperate to Impose Deletional Tolerance of Organ-Specific Antigens. *Immunity* 37, 451–462. 10.1016/j.immuni.2012.05.030 [PubMed: 22960223]
- Green DR, 2003 The suicide in the thymus, a twisted trail. *Nat. Immunol* 10.1038/ni0303-207
- Green DR, Droin N, Pinkoski M, 2003 Activation-induced cell death in T cells. *Immunol. Rev* 10.1034/j.1600-065X.2003.00051.x
- Green DR, Reed JC, Kluck RM, Bossy-wetzel E, Green DR, Newmeyer DD, 1998 Mitochondria and Apoptosis. *Science* (80-.). 281, 1309–1312. 10.1126/science.281.5381.1309
- Grosse-Wilde A, Voloshanenko O, Lawrence Bailey S, Longton GM, Schaefer U, Csernok AI, Schütz G, Greiner EF, Kemp CJ, Walczak H, 2008 TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. *J. Clin. Invest* 118, 100–110. 10.1172/JCI33061 [PubMed: 18079967]
- Grossman Z, Paul WE, 2015 Dynamic Tuning of Lymphocytes: Physiological Basis, Mechanisms, and Function. *Annu. Rev. Immunol* 33, 677–713. 10.1146/annurev-immunol-032712-100027 [PubMed: 25665077]
- Hameed A, Lowrey DM, Lichtenheld M, Podack ER, 1988 Characterization of three serine esterases isolated from human IL-2 activated killer cells. *J Immunol* 141, 3142–7. [PubMed: 3262682]
- Han J, Goldstein LA, Gastman BR, Froelich CJ, Yin XM, Rabinowich H, 2004 Degradation of Mcl-1 by granzyme B: Implications for Bim-mediated mitochondrial apoptotic events. *J. Biol. Chem* 279, 22020–22029. 10.1074/jbc.M313234200 [PubMed: 15014070]
- Han J, Goldstein LA, Gastman BR, Rabinovitz A, Rabinowich H, 2005 Disruption of Mcl-1-Bim complex in granzyme B-mediated mitochondrial apoptosis. *J. Biol. Chem* 280, 16383–16392. 10.1074/jbc.M411377200 [PubMed: 15713684]
- Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H, 1999 Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. *J Immunol* 163, 583–589. [PubMed: 10395644]

- Hashiramoto A, Konishi Y, Murayama K, Kawasaki H, Yoshida K, Tsumiyama K, Tanaka K, Mizuhara M, Shiotsuki T, Kitamura H, Komai K, Kimura T, Yagita H, Shiozawa K, Shiozawa S, 2018 A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell. *J. Biol. Chem* 293, 1933–1943. 10.1074/jbc.M117.798884 [PubMed: 29180447]
- Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K, 2001 Critical contribution of IFN- γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α -galactosylceramide. *Eur. J. Immunol* 31, 1720–1727. 10.1002/1521-4141(200106)31:6<1720::AID-IMMU1720>3.0.CO;2-U [PubMed: 11385616]
- He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X, 2009 Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF- α . *Cell* 137, 1100–1111. 10.1016/j.cell.2009.05.021 [PubMed: 19524512]
- Heibein J. a, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC, 2000 Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. *J. Exp. Med* 192, 1391–1402. 10.1084/jem.192.10.1391 [PubMed: 11085742]
- Heibein JA, Barry M, Motyka B, Bleackley RC, 1999 Granzyme B-induced loss of mitochondrial inner membrane potential ($\Delta\psi$) and cytochrome c release are caspase independent. *J. Immunol. (Baltimore, Md. 1950)* 163, 4683–4693.
- Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P, 2002 Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim. *Immunity* 16, 759–767. 10.1016/S1074-7613(02)00322-9 [PubMed: 12121658]
- Hivroz C, Chemin K, Turret M, Bohineust A, 2012 Crosstalk between T Lymphocytes and Dendritic Cells. *Crit. Rev. Immunol* 32, 139–155. 10.1615/CritRevImmunol.v32.i2.30 [PubMed: 23216612]
- Hogquist KA, Baldwin TA, Jameson SC, 2005 Central tolerance: Learning self-control in the thymus. *Nat. Rev. Immunol* 10.1038/nri1707
- Holler N, Zaru R, Micheau O, Thome M, Attinger a, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J, 2000 Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat. Immunol* 1, 489–495. 10.1038/82732 [PubMed: 11101870]
- Hoves S, Sutton VR, Haynes NM, Hawkins ED, Fernandez Ruiz D, Baschuk N, Sedelies KA, Schnurr M, Stagg J, Andrews DM, Villadangos JA, Trapani JA, 2011 A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells. *J. Immunol* 187, 1166–1175. 10.4049/jimmunol.1001670 [PubMed: 21709155]
- Hoves S, Trapani JA, Voskoboinik I, 2010 The battlefield of perforin/granzyme cell death pathways. *J. Leukoc. Biol* 87, 237–243. 10.1189/jlb.0909608 [PubMed: 19915166]
- Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV, 1996 TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. *Immunity* 4, 387–396. 10.1016/S1074-7613(00)80252-6 [PubMed: 8612133]
- Hu Q, Sader A, Parkman JC, Baldwin TA, 2009 Bim-Mediated Apoptosis Is Not Necessary for Thymic Negative Selection to Ubiquitous Self-Antigens. *J. Immunol* 10.4049/jimmunol.0902181
- Hughes P, Bouillet P, Strasser A, 2006 Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. *Curr. Dir. Autoimmun* 9, 74–94. <https://doi.org/90773> [pii] \n10.1159/000090773 [PubMed: 16394656]
- Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P, 2008 Apoptosis Regulators Fas and Bim Cooperate in Shutdown of Chronic Immune Responses and Prevention of Autoimmunity. *Immunity* 28, 197–205. 10.1016/j.immuni.2007.12.017 [PubMed: 18275830]
- Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S, 1991 The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell* 66, 233–243. 10.1016/0092-8674(91)90614-5 [PubMed: 1713127]
- Janeway CA, Travers P, Walport M, Shlomchik M, 2001 Immunobiology: The Immune System In Health And Disease. *Immuno Biol.* 5 10.1111/j.1467-2494.1995.tb00120.x
- Joekel LT, Bird PI, 2014 Are all granzymes cytotoxic in vivo? *Biol. Chem* 10.1515/hsz-2013-0238

- Joeckel LT, Wallich R, Martin P, Sanchez-Martinez D, Weber FC, Martin SF, Borner C, Pardo J, Froelich C, Simon MM, 2011 Mouse granzyme K has pro-inflammatory potential. *Cell Death Differ.* 18, 1112–1119. 10.1038/cdd.2011.5 [PubMed: 21311565]
- Johnstone RW, Ruefli AA, Lowe SW, 2002 Apoptosis: A link between cancer genetics and chemotherapy. *Cell.* 10.1016/S0092-8674(02)00625-6
- Ju S Te, Panka DJ, Cui H, Ettinger R, Ei-Khatib M, Sherrf DH, Stanger BZ., Marshak-Rothstein A, 1995 Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. *Nature.* 10.1038/373444a0
- Kaczmarek A, Vandenabeele P, Krysko DV, 2013 Necroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance. *Immunity.* 10.1016/j.immuni.2013.02.003
- Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H, 1994a Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature* 369, 31–37. 10.1038/369031a0 [PubMed: 8164737]
- Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P, 1994b Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. *Science* 265, 528–530. 10.1126/science.7518614 [PubMed: 7518614]
- Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY, 2006 Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. *Nat. Cell Biol.* 8, 1348–1358. 10.1038/ncb1499 [PubMed: 17115033]
- Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME, 1995 Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J.* 14, 5579–88. [PubMed: 8521815]
- Kishimoto H, Surh CD, Sprent J, 1998 A role for Fas in negative selection of thymocytes in vivo. *J. Exp. Med* 187, 1427–38. 10.1084/jem.187.9.1427 [PubMed: 9565635]
- Klein L, Kyewski B, Allen PM, Hogquist KA, 2014 Positive and negative selection of the T cell repertoire: What thymocytes see (and don't see). *Nat. Rev. Immunol* 10.1038/nri3667
- Knight DA, Ngiew SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ, 2013 Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. *J. Clin. Invest* 123, 1371–1381. 10.1172/JCI66236DS1 [PubMed: 23454771]
- Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K, 1999 Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. *Eur. J. Immunol* 29, 1390–1396. 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C [PubMed: 10229107]
- Korn T, Bettelli E, Oukka M, Kuchroo VK, 2009 IL-17 and Th17 Cells. *Annu. Rev. Immunol* 27, 485–517. 10.1146/annurev.immunol.021908.132710 [PubMed: 19132915]
- Kotzin BL, Babcock SK, Herron LR, 1988 Deletion of potentially self-reactive T cell receptor specificities in L3T4-, Lys-2-T cells of lpr mice. *J Exp Med* 2221–2229. [PubMed: 3264325]
- Kovacs JR, Li C, Yang Q, Li G, Garcia IG, Ju S, Roodman DG, Windle JJ, Zhang X, Lu B, 2012 Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. *Cell Death Differ.* 19, 144–152. 10.1038/cdd.2011.78 [PubMed: 21660048]
- Kovalovsky D, Pezzano M, Ortiz BD, Sant'Angelo DB, 2010 A novel TCR transgenic model reveals that negative selection involves an immediate, Bim-dependent pathway and a delayed, Bim-independent pathway. *PLoS One.* 10.1371/journal.pone.0008675
- Krammer PH, 2000 CD95's deadly mission in the immune system. *Nature.* 10.1038/35037728
- Krammer PH, Arnold R, Lavrik IN, 2007 Life and death in peripheral T cells. *Nat. Rev. Immunol* 10.1038/nri2115
- Krensky AM, Clayberger C, 2009 Biology and clinical relevance of granulysin. *Tissue Antigens* 73, 193–198. 10.1111/j.1399-0039.2008.01218.x [PubMed: 19254247]
- Kuklina EM, 2013 Molecular mechanisms of T-cell anergy. *Biochem.* 78, 144–156. 10.1134/S000629791302003X [PubMed: 23581985]
- Kurtulus S, Sholl A, Toe J, Tripathi P, Raynor J, Li KP, Pellegrini M, Hildeman DA, 2015 Bim controls IL-15 availability and limits engagement of multiple BH3-only proteins. *Cell Death Differ.* 22, 174–184. 10.1038/cdd.2014.118 [PubMed: 25124553]

- Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, Hildeman DA, 2011 Bcl-2 Allows Effector and Memory CD8⁺ T Cells To Tolerate Higher Expression of Bim. *J. Immunol* 186, 5729–5737. 10.4049/jimmunol.1100102 [PubMed: 21451108]
- Kurtulus S, Tripathi P, Opferman JT, Hildeman DA, 2010 Contracting the ‘mus cells’ - does down-sizing suit us for diving into the memory pool? *Immunol. Rev* 10.1111/j.1600-065X.2010.00920.x
- Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA, 2006 Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. *Science* (80-.). 10.1126/science.1115035
- Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH, 2003 Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL^{-/-} mice. *Nat. Immunol* 4, 255–260. 10.1038/ni894 [PubMed: 12577054]
- Laster SM, Wood JG, Gooding LR, 1988 Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. *J. Immunol* 141, 2629–34. [PubMed: 3171180]
- Lee H-W, Park S-J, Choi BK, Kim HH, Nam K-O, Kwon BS, 2002 4-1BB promotes the survival of CD8⁺ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. *J. Immunol* 169.
- Lenardo M, Chan FK-M, Hornung F, McFarland H, Siegel R, Wang J, Zheng L, 1999 MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment. *Annu. Rev. Immunol* 17, 221–253. 10.1146/annurev.immunol.17.1.221 [PubMed: 10358758]
- Lenardo MJ, 1991 Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. *Nature* 353, 858–861. 10.1038/353858a0 [PubMed: 1944559]
- Leshchiner ES, Braun CR, Bird GH, Walensky LD, 2013 Direct activation of full-length proapoptotic BAK. *Proc. Natl. Acad. Sci* 110, E986–E995. 10.1073/pnas.1214313110 [PubMed: 23404709]
- Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ, 2002 Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* 2, 183–192. 10.1016/S1535-6108(02)00127-7 [PubMed: 12242151]
- Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, Damko E, Moquin D, Walz T, McDermott A, Chan FKM, Wu H, 2012 The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. *Cell* 150, 339–350. 10.1016/j.cell.2012.06.019 [PubMed: 22817896]
- Li KP, Fähnrich A, Roy E, Cuda CM, Grimes HL, Perlman HR, Kalies K, Hildeman DA, 2017a Temporal Expression of Bim Limits the Development of Agonist-Selected Thymocytes and Skews Their TCR β Repertoire. *J. Immunol* 198, 257–269. 10.4049/jimmunol.1601200 [PubMed: 27852740]
- Li KP, Shanmuganad S, Carroll K, Katz JD, Jordan MB, Hildeman DA, 2017b Dying to protect: cell death and the control of T-cell homeostasis. *Immunol. Rev* 277, 21–43. 10.1111/imr.12538 [PubMed: 28462527]
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X, 1997 Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91, 479–489. 10.1016/S0092-8674(00)80434-1 [PubMed: 9390557]
- Lin Y, Devin A, Rodriguez Y, Liu ZG, 1999 Cleavage of the death domain kinase RIP by Caspase-8 prompts TNF-induced apoptosis. *Genes Dev.* 13, 2514–2526. 10.1101/gad.13.19.2514 [PubMed: 10521396]
- Linette GP, Hess JL, Sentman CL, Korsmeyer SJ, 1995 Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. *Blood*.
- Linkermann A, Green DR, 2014 Necroptosis. *N. Engl. J. Med* 10.1056/NEJMra1310050
- Liu RB, Engels B, Arina A, Schreiber K, Hyjek E, Schietinger A, Binder DC, Butz E, Krausz T, Rowley DA, Jabri B, Schreiber H, 2012 Densely granulated murine NK cells eradicate large solid tumors. *Cancer Res.* 72, 1964–1974. 10.1158/0008-5472.CAN-11-3208 [PubMed: 22374983]
- Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J, 2016 Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. *Nature* 535, 153–158. 10.1038/nature18629 [PubMed: 27383986]

- Liu Y, Shoji-Kawata S, Sumpter RM, Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY, Clarke PGH, Puyal J, Levine B, 2013 Autosis is a Na⁺,K⁺-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc. Natl. Acad. Sci* 110, 20364–20371. 10.1073/pnas.1319661110 [PubMed: 24277826]
- Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, Herrmann J, Wu JC, Fesik SW, 2000 Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. *Nature*. 10.1038/35050006
- Locksley RM, Killeen N, Lenardo MJ, 2001 The TNF and TNF receptor superfamilies: Integrating mammalian biology. *Cell*. 10.1016/S0092-8674(01)00237-9
- Lopez JA, Susanto O, Jenkins MR, Lukyanova N, Sutton VR, Law RHP, Johnston A, Bird CH, Bird PI, Whisstock JC, Trapani JA, Saibil HR, Voskoboinik I, 2013 Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. *Blood* 121, 2659–2668. 10.1182/blood-2012-07-446146 [PubMed: 23377437]
- Los M, Craen M Van de, Penning LC, Schenk H, Westendorp M, Baeuerle PA, DrÖge W, Krammer PH, Fiers W, Schulze-Osthoff K, 1995 Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. *Nature* 375, 81–83. 10.1038/375081a0 [PubMed: 7536901]
- Lowin B, Hahne M, Mattmann C, Tschopp J, 1994 Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. *Nature* 370, 650–652. 10.1038/370650a0 [PubMed: 7520535]
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak A Bin, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, De Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FGR, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa Y. a, Haring D., Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH., McDermott MM, McGrath J, Mensah G. a, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad A. a, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KMV, Nasser K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R., Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon J. a, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor J. a, Thomas B, Tleyjeh IM, Towbin J. a, Truelsen T, Undurraga E. a, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock M. a, Weintraub R., Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJL, 2012 Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380, 2095–2128. 10.1016/S0140-6736(12)61728-0 [PubMed: 23245604]
- Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang T-H, Kim H-M, Drake D, Liu XS, Bennett D. a, Colaiácovo MP., Yankner B. a, 2014 REST and stress resistance in ageing and Alzheimer's disease. *Nature* 507, 448–454. 10.1038/nature13163 [PubMed: 24670762]
- Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB, 1995 Bclx regulates the survival of double-positive thymocytes. *Proc. Natl. Acad. Sci. U. S. A* 92, 4763–7. 10.1073/pnas.92.11.4763 [PubMed: 7761398]
- Ma Y, Temkin V, Liu H, Pope RM, 2005 NF- κ B protects macrophages from lipopolysaccharide-induced cell death: The role of caspase 8 and receptor-interacting protein. *J. Biol. Chem* 280, 41827–41834. 10.1074/jbc.M510849200 [PubMed: 16246838]

- Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, Smyth MJ, Lollini P-L, Musiani P, Forni G, Iezzi M, Cavallo F, 2014 Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. *J. Immunol* 192, 5434–5441. 10.4049/jimmunol.1301248 [PubMed: 24790144]
- Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G, 2007 Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1. *EMBO J.* 26, 2527–2539. 10.1038/sj.emboj.7601689 [PubMed: 17446862]
- Majno G, Joris I, 1995 Apoptosis, oncosis, and necrosis. An overview of cell death. *Am. J. Pathol* <https://doi.org/7856735>
- Mak A, Kow NY, 2014 The pathology of t cells in systemic lupus erythematosus. *J. Immunol. Res* 10.1155/2014/419029
- Mariathasan S, Zakarian a, Bouchard D, Michie a M., Zúñiga-Pflücker JC, Ohashi PS, 2001 Duration and strength of extracellular signal-regulated kinase signals are altered during positive versus negative thymocyte selection. *J. Immunol* 167, 4966–73. 10.4049/jimmunol.167.9.4966 [PubMed: 11673503]
- Marinari B, Costanzo A, Marzano V, Piccolella E, Tuosto L, 2004 CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters. *Proc. Natl. Acad. Sci. U. S. A* 101, 6098–6103. 10.1073/pnas.0308688101 [PubMed: 15079071]
- Martin H, Mandron M, Davrinche C, 2008 Interplay between human cytomegalovirus and dendritic cells in T cell activation. *Med. Microbiol. Immunol* 10.1007/s00430-008-0079-0
- Martin SJ, Henry CM, Cullen SP, 2012 A Perspective on Mammalian Caspases as Positive and Negative Regulators of Inflammation. *Mol. Cell* 46, 387–397. 10.1016/j.molcel.2012.04.026 [PubMed: 22633487]
- Martínez-Lostao L, Anel A, Pardo J, 2015 How Do Cytotoxic Lymphocytes Kill Cancer Cells? *Clin. Cancer Res.* 21, 5047–5056. 10.1158/1078-0432.CCR-15-0685 [PubMed: 26567364]
- Martinon F, Burns K, Tschoep J, 2002 The Inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL- β . *Mol. Cell* 10, 417–426. 10.1016/S1097-2765(02)00599-3 [PubMed: 12191486]
- Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J, 2008 Granzyme A Cleaves a Mitochondrial Complex I Protein to Initiate Caspase-Independent Cell Death. *Cell* 133, 681–692. 10.1016/j.cell.2008.03.032 [PubMed: 18485875]
- Martinvalet D, Zhu P, Lieberman J, 2005 Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. *Immunity* 22, 355–370. 10.1016/j.immuni.2005.02.004 [PubMed: 15780992]
- Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M, 2015 T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. *J. Exp. Med* 212, 555–568. 10.1084/jem.20140857 [PubMed: 25824823]
- Metkar SS, Mena C, Pardo J, Wang B, Wallich R, Freudenberg M, Kim S, Raja SM, Shi L, Simon MM, Froelich CJ, 2008 Human and Mouse Granzyme A Induce a Proinflammatory Cytokine Response. *Immunity* 29, 720–733. 10.1016/j.immuni.2008.08.014 [PubMed: 18951048]
- Metkar SS, Wang B, Catalan E, Anderluh G, Gilbert RJC, Pardo J, Froelich CJ, 2011 Perforin rapidly induces plasma membrane phospholipid flip-flop. *PLoS One* 6 10.1371/journal.pone.0024286
- Meyer zu Horste G, Przybylski D, Schramm MA, Wang C, Schnell A, Lee Y, Sobel R, Regev A, Kuchroo VK, 2018 Fas Promotes T Helper 17 Cell Differentiation and Inhibits T Helper 1 Cell Development by Binding and Sequestering Transcription Factor STAT1. *Immunity* 48, 556–569.e7. 10.1016/j.immuni.2018.03.008 [PubMed: 29562202]
- Micheau O, Tschoep J, 2003 Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 114, 181–190. 10.1016/S0092-8674(03)00521-X [PubMed: 12887920]
- Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y, 2011 CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. *Blood* 117, 1042–1052. 10.1182/blood-2010-05-283770 [PubMed: 21045195]

- Miura M, Zhu H, Rotello R, Hartwig EA, Yuan J, 1993 Induction of apoptosis in fibroblasts by IL-1 β -converting enzyme, a mammalian homolog of the *c.elegans* cell death gene *ced-3*. *Cell* 75, 653–660. 10.1016/0092-8674(93)90486-A [PubMed: 8242741]
- Mocarski ES, Upton JW, Kaiser WJ, 2012 Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. *Nat. Rev. Immunol* 10.1038/nri3131
- Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC, 2014 IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. *Science* (80-.). 343, 428–432. 10.1126/science.1243640
- Morales-Kastresana A, Catalán E, Hervás-Stubbs S, Palazón A, Azpilikueta A, Bolaños E, Anel A, Pardo J, Melero I, 2013 Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. *J. Immunother. Cancer* 1 10.1186/2051-1426-1-3
- Murata S, Sasaki K, Kishimoto T, Niwa S. -i., Hayashi H, Takahama Y, Tanaka K, 2007 Regulation of CD8+ T Cell Development by Thymus-Specific Proteasomes. *Science* (80-.). 316, 1349–1353. 10.1126/science.1141915
- Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, Lewis R, Lalaoui N, Metcalf D, Webb AI, Young SN, Varghese LN, Tannahill GM, Hatchell EC, Majewski IJ, Okamoto T, Dobson RCJ, Hilton DJ, Babon JJ, Nicola NA, Strasser A, Silke J, Alexander WS, 2013 The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. *Immunity* 39, 443–453. 10.1016/j.immuni.2013.06.018 [PubMed: 24012422]
- Murphy K, Heimberger A, Loh D, 1990 Induction by antigen of intrathymic apoptosis of CD4+CD8+TCR α 0 thymocytes in vivo. *Science* (80-.). 250, 1720–1723. 10.1126/science.2125367
- Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM, 1996 FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. *Cell* 85, 817–827. 10.1016/S0092-8674(00)81266-0 [PubMed: 8681377]
- Nakayama K, Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, Fields LE, Lucas PJ, Stewart V, Alt FW, et al. 1993 Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. *Science* 261, 1584–8. 10.1126/science.8372353 [PubMed: 8372353]
- Newton K, Harris AW, Bath ML, Smith KGC, Strasser A, 1998 A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. *EMBO J.* 17, 706–718. 10.1093/emboj/17.3.706 [PubMed: 9450996]
- Ni Chonghaile T, Sarosiek K. a, Vo T-T, Ryan J. a, Tammareddi A, Moore VDG, Deng J, Anderson KC, Richardson P, Tai Y-T, Mitsiades CS, Matulonis U. a, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hsirsch MS, Carrasco DR, Letai A, 2011 Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. *Science* 334, 1129–33. 10.1126/science.1206727 [PubMed: 22033517]
- Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR, 2011 Catalytic activity of the caspase-8-FLIP L complex inhibits RIPK3-dependent necrosis. *Nature* 471, 363–368. 10.1038/nature09852 [PubMed: 21368763]
- Odake S, Kam CM, Narasimhan L, Powers JC, Poe M, Blake JT, Krahenbuhl O, Tschopp J, 1991 Human and Murine Cytotoxic T Lymphocyte Serine Proteases: Subsite Mapping with Peptide Thioester Substrates and Inhibition of Enzyme Activity and Cytolysis by Isocoumarins. *Biochemistry* 30, 2217–2227. 10.1021/bi00222a027 [PubMed: 1998680]
- Okouchi M, Ekshyyan O, Maracine M, Aw TY, 2007 Neuronal apoptosis in neurodegeneration. *Antioxid. Redox Signal.* 9, 1059–96. 10.1089/ars.2007.1511 [PubMed: 17571960]
- Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ, 2003 Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. *Nature* 426, 671–676. 10.1038/nature02067 [PubMed: 14668867]
- Palmer E, 2003 Negative selection - Clearing out the bad apples from the T-cell repertoire. *Nat. Rev. Immunol* 10.1038/nri1085
- Pao LI, Sumaria N, Kelly JM, van Dommelen S, Cretney E, Wallace ME, Anthony DA, Uldrich AP, Godfrey DI, Papadimitriou JM, Mullbacher A, Degli-Esposti MA, Smyth MJ, 2005 Functional

analysis of granzyme M and its role in immunity to infection. *J. Immunol* 175, 3235–43. <https://doi.org/10.1093/infdis/jii162> [pii] [PubMed: 16116214]

- Pardo J, Aguilo JI, Anel A, Martin P, Joeckel L, Borner C, Wallich R, Müllbacher A, Froelich CJ, Simon MM, 2009 The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. *Microbes Infect.* 10.1016/j.micinf.2009.02.004
- Pardo J, Balkow S, Anel A, Simon MM, 2002 Granzymes are essential for natural killer cell-mediated and perfacilitated tumor control. *Eur. J. Immunol* 32, 2881–2886. 10.1002/1521-4141(200210)32:10<2881::AID-IMMU2881>3.0.CO;2-K [PubMed: 12355441]
- Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Müllbacher A, Anel A, Simon MM, 2004 Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. *J. Cell Biol.* 167, 457–468. 10.1083/jcb.200406115 [PubMed: 15534000]
- Pardoll DM, 2012 The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer* 10.1038/nrc3239
- Park HJ, Ban YL, Byun D, Park SH, Jung KC, 2010 Interaction between the mouse homologue of CD99 and its ligand PILR as a mechanism of T cell receptor-independent thymocyte apoptosis. *Exp. Mol. Med* 10.3858/emmm.2010.42.5.037
- Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL, 2005 CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. *Mol. Cell. Biol* 25, 9543–9553. 10.1128/MCB.25.21.9543-9553.2005 [PubMed: 16227604]
- Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL, 2003 CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes. *J. Immunol* 171, 166–174. 10.4049/jimmunol.171.1.166 [PubMed: 12816995]
- Pattingre S, Tassa A, Qu X, Garuti R, Xiao HL, Mizushima N, Packer M, Schneider MD, Levine B, 2005 Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 122, 927–939. 10.1016/j.cell.2005.07.002 [PubMed: 16179260]
- Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK, 2010 Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. *Cancer Immunol. Immunother.* 59, 1235–1246. 10.1007/s00262-010-0848-7 [PubMed: 20376439]
- Pellegrini M, Belz G, Bouillet P, Strasser A, 2003 Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. *Proc. Natl. Acad. Sci* 100, 14175–14180. 10.1073/pnas.2336198100 [PubMed: 14623954]
- Peng BSL, Robert ME, Hayday AC, Craft J, 1996 A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. *J. Exp. Med* 184, 6–11. 10.1084/jem.184.3.1149
- Perry JSA, Hsieh CS, 2016 Development of T-cell tolerance utilizes both cell-autonomous and cooperative presentation of self-antigen. *Immunol. Rev* 271, 141–155. 10.1111/imr.12403 [PubMed: 27088912]
- Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC, Green DR, 2001 Granzyme B-mediated Apoptosis Proceeds Predominantly through a Bcl-2-inhibitable Mitochondrial Pathway. *J. Biol. Chem* 276, 12060–12067. 10.1074/jbc.M009038200 [PubMed: 11278459]
- Pipkin ME, Lieberman J, 2007 Delivering the kiss of death: progress on understanding how perforin works. *Curr. Opin. Immunol* 10.1016/j.coi.2007.04.011
- Pobezinsky LA, Angelov GS, Tai X, Jeurling S, Van Laethem F, Feigenbaum L, Park JH, Singer A, 2012 Clonal deletion and the fate of autoreactive thymocytes that survive negative selection. *Nat. Immunol* 10.1038/ni.2292
- Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ, 2014 Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. *Blood* 123, 1989–1999. 10.1182/blood-2013-10-535393 [PubMed: 24398331]
- Prokunina L, Castillejo-López C, Öberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdóttir H, Gróndal G, Isine Bolstad A, Svenungsson E, Lundberg I, Sturfelt G, Jönsson

- A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllenstein UB, Harley JB, Alarcón-Segovia D, Steinsson K, Alarcón-Riquelme ME, 2002 A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. *Nat. Genet* 32, 666–669. 10.1038/ng1020 [PubMed: 12402038]
- Proskuryakov SY, Konoplyannikov AG, Gabai VL, 2003 Necrosis: A specific form of programmed cell death? *Exp. Cell Res.* 10.1016/S0014-4827(02)00027-7
- Ramage P, Cheneval D, Chvei M, Graff P, Hemmig R, Heng R, Kocher HP, Mackenzie A, Memmert K, Revesz L, Wishart W, 1995 Expression, refolding, and autocatalytic proteolytic processing of the interleukin-1 beta-converting enzyme precursor. *J. Biol. Chem* 270, 9378–9383. 10.1074/jbc.270.16.9378 [PubMed: 7721861]
- Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB, 2002 Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. *Nat. Immunol* 10.1038/ni834
- Revell P. a, Grossman WJ, Thomas D. a, Cao X, Behl R, Ratner J. a, Lu ZH, Ley TJ, 2005 Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. *J. Immunol* 174, 2124–2131. <https://doi.org/10.1093/immk/174/4/2124> [pii] [PubMed: 15699143]
- Rincón M, Whitmarsh A, Yang DD, Weiss L, Dériard B, Jayaraj P, Davis RJ, Flavell RA, 1998 The JNK Pathway Regulates the In Vivo Deletion of Immature CD4⁺ CD8⁺ Thymocytes. *J. Exp. Med* 188, 1817–1830. [PubMed: 9815259]
- Rogers PR, Song J, Gramaglia I, Killeen N, Croft M, 2001 OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. *Immunity* 15, 445–455. 10.1016/S1074-7613(01)00191-1 [PubMed: 11567634]
- Ryan J, Letai A, 2013 BH3 profiling in whole cells by fluorimeter or FACS. *Methods* 61, 156–164. 10.1016/j.ymeth.2013.04.006 [PubMed: 23607990]
- Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF, 2001 c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. *J. Exp. Med* 193, 317–28. 10.1084/jem.193.3.317 [PubMed: 11157052]
- Sabbatini P, Han J, Chiou SK, Nicholson DW, White E, 1997 Interleukin 1 beta converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. *Cell Growth Differ* 8, 643–653. [PubMed: 9185998]
- Sakaguchi S, 2000 Regulatory T cells: key controllers of immunologic self-tolerance. *Cell* 101, 455–458. 10.1016/S0092-8674(00)80856-9 [PubMed: 10850488]
- Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Billie Au PY, Berry DM, Tamblyn L, Shehabeldin A, Migon E, Wakeham A, Bouchard D, Yeh WC, McGlade JC, Ohashi PS, Hakem R, 2003 Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. *Genes Dev.* 10.1101/gad.1063703
- Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, D'Angeac AD, Bacon PA, Emery P, Akbar AN, 1997 Inhibition of T cell apoptosis in the rheumatoid synovium. *J. Clin. Invest* 99, 439–46. 10.1172/JCI119178 [PubMed: 9022077]
- Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A, 2013 BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response. *Mol. Cell* 51, 751–765. 10.1016/j.molcel.2013.08.048 [PubMed: 24074954]
- Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A, 2017 Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. *Cancer Cell* 31, 142–156. 10.1016/j.ccell.2016.11.011 [PubMed: 28017613]
- Sarosiek KA, Letai A, 2016 Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise. *FEBS J.* 283, 3523–3533. 10.1111/febs.13714 [PubMed: 26996748]
- Sborgi L, Rühl S, Mulvihill E, Pipercevic J, Heilig R, Stahlberg H, Farady CJ, Müller DJ, Broz P, Hiller S, 2016 GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. *EMBO J.* 35, 1766–1778. 10.15252/embj.201694696 [PubMed: 27418190]

- Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME, 1998 Two CD95 (APO-1/Fas) signaling pathways. *EMBO J.* 17, 1675–1687. 10.1093/emboj/17.6.1675 [PubMed: 9501089]
- Scaffidi G, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME, 1999 Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. *J. Biol. Chem* 274, 22532–22538. 10.1074/jbc.274.32.22532 [PubMed: 10428830]
- Schüll S, Günther SD, Brodesser S, Seeger JM, Tosetti B, Wiegmann K, Pongratz C, Diaz F, Witt A, Andree M, Brinkmann K, Krönke M, Wiesner RJ, Kashkar H, 2015 Cytochrome c oxidase deficiency accelerates mitochondrial apoptosis by activating ceramide synthase 6. *Cell Death Dis.* 6, e1691 10.1038/cddis.2015.62 [PubMed: 25766330]
- Schultz J, Pavlovic J, Strack B, Nawrath M, Moelling K, 1999 Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. *Hum Gene Ther* 10, 407–417. 10.1089/10430349950018850 [PubMed: 10048393]
- Schweichel J-U, Merker H-J, 1973 The morphology of various types of cell death in prenatal tissues. *Teratology* 7, 253–266. 10.1002/tera.1420070306 [PubMed: 4807128]
- Seki N, Brooks AD, Carter CRD, Back TC, Parsonneault EM, Smyth MJ, Wilttrout RH, Sayers TJ, 2002 Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. *J. Immunol* 168, 3484–92. 10.4049/jimmunol.168.7.3484 [PubMed: 11907109]
- Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ, 1991 bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. *Cell.* 10.1016/0092-8674(91)90361-2
- Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wilttrout RH, Yagita H, Sayers TJ, 2009 Antigen presented by tumors in vivo determines the nature of CD8+T-cell cytotoxicity. *Cancer Res.* 69, 6615–6623. 10.1158/0008-5472.CAN-09-0685 [PubMed: 19654302]
- Sharma P, Allison JP, 2015 The future of immune checkpoint therapy. *Science* (80-.). 10.1126/science.aaa8172
- Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F, 2015 Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* 526, 660–665. 10.1038/nature15514 [PubMed: 26375003]
- Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y, 2004 Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. *Nat. Cell Biol.* 6, 1221–1228. 10.1038/ncb1192 [PubMed: 15558033]
- Simon MM, Hausmann M, Tran T, Ebnet K, Tschopp J, ThaHla R, Mullbacher A, 1997 In Vitro- and Ex Vivo-derived Cytolytic Leukocytes from Granzyme A x B Double Knockout Mice Are Defective in Granule-mediated Apoptosis but not Lysis of Target Cells. *J. Exp. Med* 186, 1781–1786. 10.1084/jem.186.10.1781 [PubMed: 9362539]
- Sin JI, Park JB, Lee IH, Park D, Choi YS, Choe J, Celis E, 2012 Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN- γ -dependent manner: Application of Trp2180–188peptides. *Cancer Immunol. Immunother.* 61, 1671–1682. 10.1007/s00262-012-1214-8 [PubMed: 22382361]
- Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS, 2001 A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. *Proc. Natl. Acad. Sci. U. S. A* 10.1073/pnas.141108798
- Smyth MJ, Cretney E, Takeda K, Wilttrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K, 2001 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. *J. Exp. Med* 193, 661–670. 10.1084/jem.193.6.661 [PubMed: 11257133]
- Smyth MJ, Street SEA, Trapani JA, 2003 Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection. *J. Immunol* 171, 515–518. 10.4049/jimmunol.171.2.515 [PubMed: 12847210]
- Smyth MJ, Taniguchi M, Street SEA, Alerts E, 2000 The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. *J. Immunol* 165, 2665–70. 10.4049/jimmunol.165.5.2665 [PubMed: 10946296]

- Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes C. a, Scalzo a a, 1999 Perforin is a major contributor to NK cell control of tumor metastasis. *J. Immunol* 162, 6658–6662. 10.4049/jimmunol.169.10.5377 [PubMed: 10352283]
- Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA, 2000 Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. *J Exp Med* 192, 755–760. 10.1084/jem.192.5.755 [PubMed: 10974040]
- Song K, Chang Y, Prud'homme GJ, 2000 IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. *Gene Ther.* 7, 1527–1535. [PubMed: 11021590]
- Spetz J, Moslehi J, Sarosiek K, 2018 Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment. *Curr. Treat. Options Cardiovasc. Med.* 20, 31 10.1007/s11936-018-0627-x [PubMed: 29556748]
- Sprent J, Kishimoto H, 2002 The thymus and negative selection. *Immunol. Rev* 10.1034/j.1600-065X.2002.18512.x
- Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES, 2002 The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. *J. Biol. Chem* 277, 21119–21122. 10.1074/jbc.C200179200 [PubMed: 11967258]
- Strasser A, Harris AW, Cory S, 1991 bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. *Cell* 67, 889–899. 10.1016/0092-8674(91)90362-3 [PubMed: 1959134]
- Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, Peters AMJ, Sneller MC, Hallahan CW, Wang J, Fischer RE, Jackson CM, Lin AY, Bäuml C, Siegert E, Marx A, Vaishnav AK, Grodzicky T, Fleisher TA, Lenardo MJ, 2001 The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. *Blood* 98, 194–200. 10.1182/blood.V98.1.194 [PubMed: 11418480]
- Street SEA, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ, 2007 Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. *Cancer Res.* 67, 5454–5460. 10.1158/0008-5472.CAN-06-4084 [PubMed: 17545627]
- Stritesky GL, Xing Y, Erickson JR, Kalekar LA, Wang X, Mueller DL, Jameson SC, Hogquist KA, 2013 Murine thymic selection quantified using a unique method to capture deleted T cells. *Proc. Natl. Acad. Sci* 10.1073/pnas.1217532110
- Su JH, Deng G, Cotman CW, 1997 Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. *J. Neuropathol. Exp. Neurol*
- Su L, Quade B, Wang H, Sun L, Wang X, Rizo J, 2014 A plug release mechanism for membrane permeation by MLKL. *Structure* 22, 1489–1500. 10.1016/j.str.2014.07.014 [PubMed: 25220470]
- Suda T, Takahashi T, Golstein P, Nagata S, 1993 Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell* 75, 1169–1178. 10.1016/0092-8674(93)90326-L [PubMed: 7505205]
- Suen AYW, Baldwin TA, 2012 Proapoptotic protein Bim is differentially required during thymic clonal deletion to ubiquitous versus tissue-restricted antigens. *Proc. Natl. Acad. Sci* 10.1073/pnas.1114834109
- Sugawara T, Moriguchi T, Nishida E, Takahama Y, 1998 Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. *Immunity* 9, 565–574. [https://doi.org/S1074-7613\(00\)80639-1](https://doi.org/S1074-7613(00)80639-1) [pii] [PubMed: 9806642]
- Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X, 2012 Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* 148, 213–227. 10.1016/j.cell.2011.11.031 [PubMed: 22265413]
- Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, Trapani JA, 2000 Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. *J. Exp. Med* 192, 1403–14. 10.1084/jem.192.10.1403 [PubMed: 11085743]

- Sutton VR, Wowk ME, Cancilla M, Trapani JA, 2003 Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. *Immunity* 18, 319–329. 10.1016/S1074-7613(03)00050-5 [PubMed: 12648450]
- Tait SWG, Green DR, 2013 Mitochondrial regulation of cell death. *Cold Spring Harb. Perspect. Biol* 5, a008706 10.1101/cshperspect.a008706 [PubMed: 24003207]
- Takaba H, Takayanagi H, 2017 The Mechanisms of T Cell Selection in the Thymus. *Trends Immunol.* 38, 805–816. 10.1016/j.it.2017.07.010 [PubMed: 28830733]
- Takada K, Takahama Y, 2015 Positive-selection-inducing self-peptides displayed by cortical thymic epithelial cells. *Adv. Immunol* 125, 87–110. 10.1016/bs.ai.2014.09.003 [PubMed: 25591465]
- Takahama Y, Takada K, Murata S, Tanaka K, 2012 β 5t-containing thymoproteasome: Specific expression in thymic cortical epithelial cells and role in positive selection of CD8+ T cells. *Curr. Opin. Immunol* 10.1016/j.coi.2012.01.006
- Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K, 2001 Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. *Nat. Med* 7, 94–100. 10.1038/83416 [PubMed: 11135622]
- Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K, 2002 Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. *J. Exp. Med* 195, 161–9. 10.1084/jem.20011171 [PubMed: 11805143]
- Tarasenko TN, Pacheco SE, Koenig MK, Gomez-Rodriguez J, Kapnick SM, Diaz F, Zerfas PM, Barca E, Sudderth J, DeBerardinis RJ, Covian R, Balaban RS, DiMauro S, McGuire PJ, 2017 Cytochrome c Oxidase Activity Is a Metabolic Checkpoint that Regulates Cell Fate Decisions During T Cell Activation and Differentiation. *Cell Metab.* 25, 1254–1268.e7. 10.1016/j.cmet.2017.05.007 [PubMed: 28591633]
- Taylor RC, Cullen SP, Martin SJ, 2008 Apoptosis: Controlled demolition at the cellular level. *Nat. Rev. Mol. Cell Biol.* 10.1038/nrm2312
- Torán JL, Sánchez-Pulido L, Kremer L, Del Real G, Valencia A, Martínez-A C, 2001 Granzyme A and B-deficient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo anti-tumor capacity. *Eur. J. Immunol* 31, 39–47. 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1 [PubMed: 11169436]
- Trapani JA, Thia KYT, Andrews M, Davis ID, Gedye C, Parente P, Svobodova S, Chia J, Browne K, Campbell IG, Phillips WA, Voskoboinik I, Cebon JS, 2013 Human perforin mutations and susceptibility to multiple primary cancers. *Oncoimmunology* 2 10.4161/onci.24185
- Trauth B, Klas C, Peters A, Matzku S, Moller P, Falk W, Debatin K, Krammer P, 1989 Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science* (80-.). 245, 301–305. 10.1126/science.2787530
- Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Röder C, Kalthoff H, Wajant H, 2006 TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. *Oncogene* 25, 7434–7439. 10.1038/sj.onc.1209719 [PubMed: 16751802]
- Tschopp J, Martinon F, Burns K, 2003 NALPs: A novel protein family involved in inflammation. *Nat. Rev. Mol. Cell Biol.* 10.1038/nrm1019
- Tsujimoto Y, Cossman J, Jaffe E, Croce CM, 1985 Involvement of the bcl-2 gene in human follicular lymphoma. *Science* (80-.). 228, 1440–1443. 10.1126/science.3874430
- Upton JW, Kaiser WJ, Mocarski ES, 2012 DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. *Cell Host Microbe* 11, 290–297. 10.1016/j.chom.2012.01.016 [PubMed: 22423968]
- van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H, 1996 Decreased tumor surveillance in perforin-deficient mice. *J. Exp. Med* 184, 1781–90. 10.1084/jem.184.5.1781 [PubMed: 8920866]
- Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G, 2010 Molecular mechanisms of necroptosis: An ordered cellular explosion. *Nat. Rev. Mol. Cell Biol.* 10.1038/nrm2970
- Vaux DL, Cory S, Adams JM, 1988 Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 335, 440–442. 10.1038/335440a0 [PubMed: 3262202]

- Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ, 1993 Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. *Cell* 75, 229–240. 10.1016/0092-8674(93)80065-M [PubMed: 8402909]
- Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, Requena T, Swiatecka D, Wichers H, 2015 The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models, The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. 10.1007/978-3-319-16104-4
- von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H, 2015 Cancer cell-autonomous TRAIL-R signaling promotes KRAS-Driven cancer progression, invasion, and metastasis. *Cancer Cell* 27, 561–573. 10.1016/j.ccell.2015.02.014 [PubMed: 25843002]
- Voskoboinik I, Smyth MJ, Trapani JA, 2006 Perforin-mediated target-cell death and immune homeostasis. *Nat. Rev. Immunol* 10.1038/nri1983
- Voskoboinik I, Thia M-C, De Bono A, Browne K, Cretney E, Jackson JT, Darcy PK, Jane SM, Smyth MJ, Trapani JA, 2004 The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene. *J. Exp. Med* 200, 811–816. 10.1084/jem.20040776 [PubMed: 15365097]
- Voskoboinik I, Whisstock JC, Trapani JA, 2015 Perforin and granzymes: Function, dysfunction and human pathology. *Nat. Rev. Immunol* 10.1038/nri3839
- Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, Wang FS, Wang X, 2014 Mixed Lineage Kinase Domain-like Protein MLKL Causes Necrotic Membrane Disruption upon Phosphorylation by RIP3. *Mol. Cell* 54, 133–146. 10.1016/j.molcel.2014.03.003 [PubMed: 24703947]
- Wang J, Zheng L, Lobito A, Chan FKM, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ, 1999 Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. *Cell* 98, 47–58. 10.1016/S0092-8674(00)80605-4 [PubMed: 10412980]
- Wang K, 2014 Molecular mechanisms of liver injury: Apoptosis or necrosis. *Exp. Toxicol. Pathol* 66, 4–9. 10.1016/j.etp.2014.04.004
- Wang X, 2001 The expanding role of mitochondria in apoptosis. *Genes Dev.* 15, 2922–2933. [PubMed: 11711427]
- Wange RL, Samelson LE, 1996 Complex complexes: Signaling at the TCR. *Immunity.* 10.1016/S1074-7613(00)80315-5
- Waterhouse NJ, Sutton VR, Sedelies KA, Ciccone A, Jenkins M, Turner SJ, Bird PI, Trapani JA, 2006 Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. *J. Cell Biol.* 173, 133–144. 10.1083/jcb.200510072 [PubMed: 16606695]
- Watson PR, Gautier AV, Paulin SM, Bland AP, Jones PW, Wallis TS, 2000 Salmonella enterica serovars Typhimurium and Dublin can lyse macrophages by a mechanism distinct from apoptosis. *Infect. Immun* 68, 3744–3747. 10.1128/IAI.68.6.3744-3747.2000 [PubMed: 10816540]
- Weant AE, Michalek RD, Khan IU, Holbrook BC, Willingham MC, Grayson JM, 2008 Apoptosis Regulators Bim and Fas Function Concurrently to Control Autoimmunity and CD8+ T Cell Contraction. *Immunity* 28, 218–230. 10.1016/j.immuni.2007.12.014 [PubMed: 18275832]
- Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ, 2000 tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. *Genes Dev.* 14, 2060–2071. 10.1101/gad.14.16.2060 [PubMed: 10950869]
- Weinlich R, Dillon CP, Green DR, 2011 Ripped to death. *Trends Cell Biol.* 10.1016/j.tcb.2011.09.002
- Wensveen FM, van Gisbergen KPJM, Derks IAM, Gerlach C, Schumacher TN, van Lier RAW, Eldering E, 2010 Apoptosis threshold set by noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. *Immunity* 32, 754–765. 10.1016/j.immuni.2010.06.005 [PubMed: 20620942]

- Werlen G, Hausmann B, Naeher D, Palmer E, 2003 Signaling life and death in the thymus: Timing is everything. *Science* (80-.). 10.1126/science.1067833
- Werlen G, Hausmann B, Palmer E, 2000 A motif in the $\alpha\beta$ T-cell receptor controls positive selection by modulating ERK activity. *Nature* 406, 422–426. 10.1038/35019094 [PubMed: 10935640]
- Whelan RS, Kaplinskiy V, Kitsis RN, 2010 Cell death in the pathogenesis of heart disease: mechanisms and significance. *Annu. Rev. Physiol* 72, 19–44. 10.1146/annurev.physiol.010908.163111 [PubMed: 20148665]
- Wirawan E, Vande Walle L, Kersse K, Cornelis S, Claerhout S, Vanoverberghe I, Roelandt R, De Rycke R, Verspurten J, Declercq W, Agostinis P, Vanden Berghe T, Lippens S, Vandenabeele P, 2010 Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. *Cell Death Dis.* 10.1038/cddis.2009.16
- Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA, 2006 Bim mediates apoptosis of CD127^{lo} effector T cells and limits T cell memory. *Eur. J. Immunol* 36, 1694–1706. 10.1002/eji.200635897 [PubMed: 16761315]
- Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, Finkelman FD, Hildeman DA, 2007 Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. *J. Exp. Med* 204, 1665–1675. 10.1084/jem.20070618 [PubMed: 17591857]
- Wong WW-L, Puthalakath H, 2008 Bcl-2 family proteins: The sentinels of the mitochondrial apoptosis pathway. *IUBMB Life* 60, 390–397. 10.1002/iub.51 [PubMed: 18425793]
- Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y, 2000 Structural basis of IAP recognition by Smac/DIABLO. *Nature*. 10.1038/35050012
- Wyllie AH, 1980 Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature*. 10.1038/284555a0
- Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y, 2005 Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. *Hum. Mol. Genet* 14, 3499–3506. 10.1093/hmg/ddi379 [PubMed: 16221758]
- Yang WS, Stockwell BR, 2016 Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol.* 26, 165–176. 10.1016/j.tcb.2015.10.014 [PubMed: 26653790]
- Yang X, Chang HY, Baltimore D, 1998 Autoproteolytic activation of pro-caspases by oligomerization. *Mol. Cell* 1, 319–325. 10.1016/S1097-2765(00)80032-5 [PubMed: 9659928]
- Yang Y, Mercep M, Ware CF, Ashwell JD, 1995 Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. *J. Exp. Med* 181, 1673–1682. 10.1084/jem.181.5.1673 [PubMed: 7536793]
- Yonehara S, Ishii A, Yonehara M, 1989 A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. *J. Exp. Med* 169, 1747–1756. 10.1084/jem.169.5.1747 [PubMed: 2469768]
- Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, Wu C, Karwacz K, Xiao S, Jorgolli M, Gennert D, Satija R, Shakya A, Lu DY, Trombetta JJ, Pillai MR, Ratcliffe PJ, Coleman ML, Bix M, Tantin D, Park H, Kuchroo VK, Regev A, 2013 Dynamic regulatory network controlling TH17 cell differentiation. *Nature* 496, 461–468. 10.1038/nature11981 [PubMed: 23467089]
- Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU, 2006 Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. *Nat. Cell Biol.* 8, 1124–1132. 10.1038/ncb1482 [PubMed: 16998475]
- Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J, 2009 RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. *Science* (80-.). 325, 332–336. 10.1126/science.1172308
- Zhang N, He Y-W, 2005 The Antiapoptotic Protein Bcl-xL Is Dispensable for the Development of Effector and Memory T Lymphocytes. *J. Immunol* 174, 6967–6973. 10.4049/jimmunol.174.11.6967 [PubMed: 15905539]
- Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu Z-G, 2012 Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc. Natl. Acad. Sci* 109, 5322–5327. 10.1073/pnas.1200012109 [PubMed: 22421439]

- Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ, 1995 Induction of apoptosis in mature T cells by tumour necrosis factor. *Nature*. 10.1038/377348a0
- Zheng L, Li J, Lenardo M, 2017 Restimulation-induced cell death: new medical and research perspectives. *Immunol. Rev* 277, 44–60. 10.1111/imr.12535 [PubMed: 28462523]
- Zheng L, Trageser CL, Willerford DM, Lenardo MJ, 1998 T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. *J. Immunol* 160, 763–9. [PubMed: 9551911]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1: Maturation and selection of T cells.

T cells originate from haematopoietic stem cells, formed in the bone marrow. Haematopoietic progenitor cells are expanded into immature thymocytes (lacking CD4, CD8 and TCR) in the cortex of the thymus. These are developed into double-positive (CD4⁺, CD8⁺) thymocytes which express TCR with different affinity for different MHC. Double-positive thymocytes go through positive selection by exposure to self MHC–endogenous peptide complexes (expressed mainly on thymic epithelial cells). Thymocytes which recognise and interact with MHC receive survival signals from the thymic epithelial cells,

while thymocytes with no recognition of MHC fail to receive the survival signals and are eliminated via apoptosis (“death by neglect”). The positively selected T cells migrate through the thymic medulla and undergo negative selection, where self-reactive T cells are culled. T cells (with CD4 or CD8 expression) which bind with high affinity to self-MHC complexes on thymic antigen-presenting cells are eliminated, while remaining CD4⁺ and CD8⁺ T cells are released into the periphery.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2: Mechanisms of T cell-mediated cell death.

cT cells can eliminate other cells via granule exocytosis and/or the expression and release of death ligands. Granule exocytosis entails release of e.g. granzymes and perforin (PRF1) toward the contact site of the target infected/dysfunctional cell. The granzymes then enter the cell and are capable of inducing cell death via multiple different pathways, with granzyme B-induced apoptosis being the most commonly observed. Death ligand secretion (of e.g. FAS ligand or TRAIL) is also a possible mode of elimination. In this case, cell death

is most often induced via the extrinsic apoptotic pathway, although it may in some contexts lead to necroptosis.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript